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ABSTRACT 
 
The aim of this paper was to evaluate vaccine efficacy under field 
conditions against Staphylococcus aureus and Coagulase Negative 
Staphylococci (CNS) intramammary infections (IMI) in dairy cows. During 
the 21-month duration of the study, 1,156 lactations in 809 cows were 
identified in two herds. At the beginning of the trial, all cows that were due 
to calve were vaccinated until approximately 50% of cows in the milking 
herd were vaccinated (~6 months). At that point in time (50% vaccination 
coverage was reached), cows were systemically random assigned to be 
vaccinated or left as negative controls. Cows that were vaccinated got the 
1st injection 45 days (+ 3 days) before the expected parturition date, the 
2nd injection 35 days (5 weeks) thereafter (+ 3 days), corresponding to 10 
days before the expected parturition date and 3rd vaccination was done at 
52 days (+ 3 days) after the actual parturition date. Cure rate, risk of new 
infections, prevalence, incidence and duration of infections were analyzed. 
The farms showed a large difference in management to control infection 
during the study. In conclusion vaccination reduced the basic reproduction 
ratio of Staph. aureus by approximately 45% and for CNS by approximately 
35%. Vaccination is a valuable tool in improving the incidence and 
prevalence of staphylococcal infection in herds. Vaccine utilization will 
need to be combined with excellent milking procedures, culling of known 
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infected cattle and other management procedures to further reduce 
incidence and duration of infection. 
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1.INTRODUCTION 
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Mastitis remains a major challenge to the worldwide dairy industry despite 
the widespread implementation of mastitis control strategies. The last forty 
years have seen a dramatic decrease in clinical mastitis incidence 
however, all accompanied by a concomitant change in the relative and 
absolute weight of different pathogens involved in this disease (Bradley, 
2002). Bovine mastitis, defined as “inflammation of the mammary gland”, 
can have an infectious or non-infectious etiology. Causative agents as 
bacteria, mycoplasma, yeasts and algae have been implicated in the 
development of the disease; Watts (1988) identified 137 different 
organisms as a cause of mastitis (Bradley, 2002). Clinical mastitis is an 
ongoing problem in many dairy herds around the world, in addition to 
reduced cow welfare and increased veterinary costs, episodes of clinical 
mastitis are associated with markedly reduced milk production (Houben et 
al., 1993; Bar et al., 2007; Hagnestam et al., 2007; Schukken et al., 2009b), 
decreased fertility (Santos et al., 2004; Hertl et al., 2010), and increased 
risk of culling and death (Waage et al., 2000; Hertl et al., 2011). Classically, 
mastitis pathogens have been classified as either contagious or 
environmental (Blowey & Edmondson, 1995). Contagious pathogens can 
be considered as organisms adapted to survive within the host, in particular 
within the mammary gland. They are able of establishing sub-clinical 
infections, which occurring as an increase in the somatic cell count 
(leukocytes [predominantly neutrophils] and epithelial cells) of milk from the 
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affected quarter; they are typically spread from cow to cow during milking 
time (Radostits et al., 1994). Conversely, the environmental pathogens are 
best described as opportunistic pathogens of the mammary gland, not 
adapted to survival within the host; typically, they invade, multiply, elicit a 
host immune response and are quickly eliminated. However, there is now 
an increasing body of evidence, to suggest that this classification may not 
be as clear cut as previously thought (Bradley, 2002).  
The primary contagious pathogens are Streptococcus agalactiae, 
Staphylococcus aureus and Mycoplasma species while primary 
environmental pathogens include two types of bacteria: coliform bacteria 
and species of streptococci other than S. agalactiae. These other 
streptococci are referred to as the "environmental streptococci". The 
primary source of environmental pathogens is the surroundings in which a 
cow lives. Soil, manure, bedding, calving pads and water host bacteria that 
cause environmental mastitis. 
 The sources of contagious mastitis, however, are infected cows and 
transmission is from cow to cow. Therefore, methods of control developed 
for the contagious pathogens are not effective against environmental 
pathogens (NMC, 1997). 
Some Staphylococcus species are known to be able to induce bovine 
mastitis, leading to severe financial losses for the dairy farmer (Bradley, 
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2002). Besides Staph. aureus, a coagulase-positive pathogenic 
Staphylococcus species with a well described aetiology in the development 
of mastitis (Barkema et al.,2006), coagulase-negative staphylococci (CNS) 
can influence udder health (Taponen et al., 2009; Thorberg et al., 2009; 
Supré et al., 2009; Piessens et al., 2012). They are omnipresent in the 
cow’s environment and on the teat end of dairy cows but are not 
necessarily associated with mastitis (Piessens et al., 2011; Braem et al., 
2012, 2013). Although their role in the development of mastitis is becoming 
increasingly important, it is apparent that only a limited number of CNS 
species cause most cases of mastitis (Supré et al., 2011). Knowing this 
knowledge and how much mastitis is important for dairy farm, we will look 
forward Staphylococcal bacteria to try to understand why this bacterial 
genus is the most important for milk quality. 
 
1.1. Staphylococcus genus 
 
Staphylococci have been isolated sporadically from a wide variety of 
environmental sources such as soil, beach sand, seawater, fresh water, 
plant surfaces and products, feeds, meat and poultry, dairy products, and 
on the surfaces of cooking ware, utensils, furniture, clothing, blankets, 
carpets, linens, paper currency, and dust and air in various inhabited areas. 
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Ogston (1883) introduced the name Staphylococcus (staphyle, bunch of 
grapes) for the group micrococci causing inflammation and suppuration. 
He was the first to differentiate two kinds of pyogenic cocci: one arranged 
in groups or masses was called “Staphylococcus” and another arranged in 
chains was named “Billroth’s Streptococcus.” Rosenbach (1884) provided 
a formal description of the genus Staphylococcus. He divided the genus 
into the two species Staph. aureus and Staph. albus. Zopf (1885) placed 
the mass-forming staphylococci and tetrad-forming micrococci in the genus 
Micrococcus. Flügge (1886) separated the genus Staphylococcus from 
Micrococcus. He differentiated the two genera mainly on the basis of their 
action on gelatin and on relation to their hosts. Staphylococci liquefied 
gelatin and were parasitic or pathogenic or both whereas micrococci were 
variable in their action on gelatin and were saprophytic. The genera 
Staphylococcus, Micrococcus and Planococcus, containing Gram-positive, 
catalase-positive cocci, were later placed in the family Micrococcaceae. 
Evans et al. (1955) proposed separating staphylococci from micrococci on 
the basis of their relation to oxygen. The facultative anaerobic cocci were 
placed in the genus Staphylococcus and the obligate aerobic cocci in the 
genus Micrococcus. By the mid-1960s, a clear distinction could be made 
between staphylococci and micrococci on the basis of their DNA base 
composition (Silvestri and Hill, 1965). Until the early 1970s, the genus 
Staphylococcus consisted of three species: the coagulase-positive species 
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Staph. aureus and the coagulase-negative species Staph. epidermidis and 
Staph. saprophyticus, but a deeper look into the chemotaxonomic and 
genotypic properties of staphylococci led to the description of many new 
staphylococcal species. 
Actually, more than 50 Staphylococcus species and subspecies have been 
characterized. The genus is divided into coagulase-positive staphylococci 
(CPS) and coagulase-negative staphylococci (CNS) based on their ability 
to coagulate rabbit plasma. The major pathogen, Staphylococcus aureus, 
is generally coagulase- positive although coagulase-negative strains of 
Staph. aureus do occur (Fox et al., 1996). Some other Staphylococcus 
species, including Staph. hyicus, may also be coagulase- positive (Hajek, 
1976; Devriese et al., 1978, 2005). In some herds, coagulase-positive 
Staph. hyicus may represent a marked proportion of CPS isolates 
(Roberson et al., 1996). Although misclassification of species can occur 
when the classification is based on the coagulase test only, the 
classification of staphylococci into two groups, CPS or Staph. aureus on 
the one hand and CNS or Staphylococcus spp. on the other hand, has been 
considered sufficient because CNS usually only cause subclinical or mild 
clinical mastitis.  
 
1.2.Staphylococcus aureus 
12 
 
 
Staph. aureus is worldwide one of the most important mastitis pathogens 
in cattle, involving in large economic loss (Halasa et al., 2007; Hogeveen 
et al., 2011). Staph. aureus is a contagious udder pathogen that spreads 
within and among cows especially during milking (Barkema et al., 2009; 
Capurro et al., 2010) and is one of the most important agent of subclinical, 
clinical, recurrent, and chronic mastitis in dairy cattle. In several studies, it 
was shown that Staph. aureus strains isolated from bovine intramammary 
infection are able to form a bacterial biofilm (Vasudevan et al., 2003; Fox 
et al., 2005; Melchior et al., 2006a). This feature is related to the 
development of persistent infections (Stewart, 2002; Melchior et al., 
2006b). 
Studies about the persistence of Staph. aureus in dairy herds have 
revealed that a limited number of Staph. aureus strains are usually 
harbored in individual herds, suggesting that these specific strains may 
possess resistance or virulence mechanisms that allow them to survive 
under the environmental or sanitation conditions of particular dairy farms 
(Matthews et al., 1994; Sommerhäuser et al., 2003; Anderson and Lyman, 
2006). 
 
1.2.1.Staph. aureus diagnosis 
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Infected cows and quarters are normally identified through bacteriological 
examination of milk samples. A common strategy to identify Staph. aureus 
-positive udder quarters is to sample cows with elevated SCC, but it is not 
uncommon that bacteria are not detected in such samples. One reason for 
this is that the concentration of bacteria in milk of an infected quarter is not 
static and infected quarters may show a sinusoidal shedding pattern as 
shown by bacteriological culturing and real-time quantitative PCR (Sears 
et al., 1990; Daley et al., 1991; Studer et al., 2008). To increase the 
probability of detecting Staph. aureus in a single milk sample, various 
methods involving, for example, preen enrichment in broth, centrifugation 
and culturing of sediment, culturing of larger volumes of milk, or freezing 
have been tested with varying results (Dinsmore et al., 1992; Zecconi et 
al., 1997; Sol et al., 2002). Recently, promising results have been obtained 
with methods based on PCR techniques (Graber et al., 2007; Studer et al., 
2008; Taponen et al., 2009), but most routine laboratories still use 
bacteriological culturing as the primary method to isolate Staph. aureus. 
Accurate and easy-to-perform methods for routine bacteriological culturing 
of milk samples for identification of Staph. aureus positive quarters and 
cows are essential for udder health control programs aiming at reducing 
the spread of Staph. aureus between cows within and between dairy herds. 
The results show that incubation of the milk sample at 37°C for 18 h, with 
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or without previous freezing of the sample before culturing, significantly 
improved the ability to isolate Staph. aureus. Using this incubation method, 
the number of Staph. aureus positive udder quarters and cows increased 
50 and 29%, respectively, compared with using the standard method 
(direct culture of 10 μL of milk). 
Many samples with low numbers of Staph. aureus are not detected by the 
standard method, but can be detected by the improved method described 
and that the essential difference is the extra incubation step before 
culturing. 
Samples identified only by the INC method had no or trace CMT reaction 
more often compared with samples detected by the standard method 
(Artursson et al., 2010). Samples with no or trace CMT reaction would not 
normally have been sent for bacteriological analysis by the practitioner, as 
the most common routine is to select quarters with a higher CMT reaction. 
Thus, udder quarters with no or slight CMT reaction should be considered 
as possible reservoirs for Staph. aureus, which could be of importance in 
tracing infected cows. However, further studies are needed to clarify if the 
bacteria identified in samples with low CMT reactions actually represent 
true IMI. The possibility of contamination from teat openings and skin 
should also be considered. 
In the study of Artursson et al. (2010), overnight freezing did not increase 
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the number of Staph. aureus -positive samples. This is in line with 
Bashandy and Heider (1979), Schukken et al. (1989), and Murdough et al. 
(1996), but in contrast to Villanueva et al. (1991), who isolated Staph. 
aureus more frequently when milk samples had been frozen for 23 d. The 
positive effect of freezing has been suggested to be an effect of disrupted 
bacterial cell aggregates, increasing the number of colony-forming units 
per milliliter, or the release of phagocytized bacteria from lysed cells 
(Villanueva et al. 1991). Artursson and colleague (2010) found significantly 
more Staph. aureus -positive samples when freezing of milk samples was 
followed by an incubation step before culturing compared with the standard 
method, which is in line with Sol et al. (2002). But, as already mentioned, 
freezing before incubation did not improve the probability of finding Staph. 
aureus -positive samples compared with incubation only. Various methods 
exist to subtype Staph. aureus. Phenotyping such as antibiotic 
susceptibility testing, or checking for production of SETs (Cenci-Goga et 
al., 2003) become more and more replaced by DNA based methods. They 
include pulsed-field gel electrophoresis (PFGE) (Anderson et al., 2006; 
Haveri et al., 2007), binary typing (Zadoks et al., 2000), multilocus 
sequence typing (MLST) (Enright et al., 2000) or DNA arrays (Monecke 
and Ehricht, 2005). In addition, PCR based methods (PCR: polymerase 
chain reaction) have been used. The latter include random or specific 
amplification of polymorphic DNA (Stepan et al., 2004). One method 
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repeatedly used to genotype Staph. aureus is PCR amplification of the 
16S–23S rRNA intergenic spacer (RS–PCR) as originally described by 
(Jensen et al., 1993). Its discriminatory power is very similar to the one of 
PFGE (Kumari et al., 1997), a proposed reference method in genotyping 
Staph. aureus (Weller 2000). In contrast to PFGE, the RS–PCR allows a 
high sample throughput. 
Of particular clinical importance is the question concerning the existence 
of subtypes of Staph. aureus responsible for IMI, which differ with respect 
to their pathogenic and contagious properties, requiring different strategies 
towards prevention and treatment of the intramammary infection. 
 
1.2.2.Staphylococcus aureus genotypes  
 
Many different strains of Staph. aureus exist, as shown by a large variety 
of strain-typing methods (Aarestrup et al., 1995; Zadoks et al., 2002b; 
Smith et al., 2005). In most herds, one strain of Staph. aureus 
predominates, due to the contagious nature of such strains, but the 
predominant strain usually coexists with a number of other Staph. aureus 
strains (Zadoks et al., 2000). In vivo, strains differ in their ability to spread 
within herds (Smith et al., 1998) and in their ability to cause SCC elevation, 
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clinical mastitis, or persistent infections (Zadoks et al., 2000; Haveri et al., 
2005) or milk production losses (Middleton and Fox, 2001). 
Analysis of the 16S–23S rRNA intergenic spacer region by RS–PCR 
revealed 17 different genotypes and 2 sub-types (a selection of 13 types is 
shown in Fig. 1). Out of them, type B and C were the most frequent ones 
as they made up 80.2% of all the isolates (genotype B: 30 isolates; 
genotype C: 51 isolates). The other 15 genotypes occurred only rarely 
ranging between 1.0% and 4.0% (equivalent to 1 to 4 strains). For further 
analysis, the rare genotypes were grouped together and were named ‘other 
genotypes’ (OG). 
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Figure n.1 - Genotypes. Electrophoresis of various PCR products of the 16S–
23S rRNA intergenic spacer region run in the DNA 7500 LabChip (Fournier 
et al., 2008) 
 
 
According to our study, the cow and quarter prevalence depended strongly 
on the genotype (p < 0.001). Indeed, genotype B was exclusively observed 
in herds having real problems with IMI caused by Staph. aureus, as the 
prevalence on cow (up to 65%) and quarter level (up to 37%) were always 
very high. Frequently more than 1 quarter per cow was infected. These 
observations are in clear contrast to those made for genotype C and OG. 
In the latter cases, IMI was restricted to 1 or very few cows per herd 
resulting therefore in low prevalence. Constantly 1 quarter per cow was 
infected. Based on these results is possible to conclude that Staph. aureus 
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of genotype B is much more contagious than the C or OG types; genotype 
B affects whole herds, genotype C and OG single animals. IMI caused by 
type B Staph. aureus is almost exclusively a single infection whereas in 
half of the cases infection with genotype C or OG is frequently associated 
with additional mastitis-relevant pathogens. These findings, however, do 
not proof that the latter types are apathogenic. Actually SCC analysis of 
pure Staph. aureus IMI demonstrated that most of the C and the majority 
of the OG genotypes were associated with counts above 100,000 cells/ml, 
the upper limit of physiological SCC (Hamann 2003). 
Actually, Staph. aureus has largely been diagnosed and monitored by 
single-quarter milk samples using an aseptic sample technique and 
bacteriological culturing. However, this procedure is both laborious and 
time consuming. In addition, the cyclic shedding of Staph. aureus (Studer 
et al., 2008) and dead bacteria have a negative effect on the diagnostic 
susceptibility of conventional bacteriology (Graber et al., 2007). Although 
repeated sampling, in individual cows it still remains between 41 and 100% 
(Sears et al., 1990) or even, increases susceptibility lower (Studer et al., 
2008). 
With the development of a ribosomal spacer PCR (RS-PCR) by Fournier 
et al. (2008), initially 17 Staph. aureus subtypes were isolated from milk 
samples of mastitic cows in Switzerland. Genotypes B (GTB) and C (GTC) 
were predominant; the other 15 genotypes were rare (Fournier et al., 2008). 
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The same descriptive study as well as the prospective one of Graber et al. 
(2009) further revealed that Staph. aureus GTB is udder-associated and 
contagious, leading to herd problems, whereas Staph. aureus GTC and 
most of the other genotypes cause single-quarter infections, or are even 
nonpathogenic. Staphylococcus aureus GTB typically possesses the 
known enterotoxin genes sea and sed, as well as a polymorphism within 
the leucotoxin E gene (lukE, lukEB), as described by Fournier et al. (2008) 
and Graber et al. (2009). These genetic characteristics have been used to 
develop a novel analytical approach based on real-time quantitative PCR 
(qPCR), which is highly sensitive and specific for Staph. aureus GTB (Boss 
et al., 2011). All other genotypes, as well as the other mastitis pathogens, 
including Staphylococcus spp., could be unequivocally excluded (Boss et 
al., 2011). Moreover, the high susceptibility allows the assay to be applied 
to bulk tank milk (BTM), where the amount of Staph. aureus is often low. 
The calculated detection limit of the novel assay in BTM is 1 Staph. aureus 
-positive cow among 138 cows (Boss et al., 2011). Bulk tank milk was 
chosen because bulk milk sampling saves work and expense, and is easy 
to collect. In addition, BTM reflects the status of the herd, provided the milk 
of all lactating cows is delivered to the tank. Milk samples lacking this 
theoretical restriction are pools of milk obtained from each single cow of a 
herd, as used in the current study: 1) a herd pool of milk taken from all 
single quarters before milking (QTRpool) or 2) a herd pool of 4-quarter milk 
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samples taken from each cow (COWpool) taken during milking. Staph. 
aureus GTB causes considerable financial loss in dairy farming. Typically, 
half of the cows in any affected herd will be infected with this pathogen 
(Fournier et al., 2008; Graber et al., 2009). Moreover, treatment success is 
generally low (Gruet et al., 2001; Sears and McCarthy, 2003) and this leads 
to a high culling and replacing rate of GTB-positive cows. The contagious 
nature of Staph. aureus GTB is in clear contrast to the other genotypes, as 
these typically either only infect single cows or lack pathogenicity 
altogether (Fournier et al., 2008; Graber et al., 2009). Consequently, these 
other genotypes are of very limited importance as a contagious agent 
causing mastitis. 
 
1.2.3.Management of Staphylococcus aureus infections  
 
The prevalence of IMI with Staph. aureus can be reduced through 
implementation of the 5-point-plan program (Hillerton et al., 1995; Zadoks 
et al., 2002a). This program, developed in the 1960s (Neave et al., 1969) 
and later extended to the 10-point-plan program (National Mastitis Council, 
2001), covers effective udder health management practices for control of 
all mastitis pathogens. For contagious organisms such Staph. aureus, 
proper milking procedures, use of post-milking teat disinfectants, 
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biosecurity to prevent introduction of pathogens and segregation or culling 
of chronically infected animals, are important aspects of these plans. 
Failure to control Staph. aureus mastitis may be caused by failure in the 
10-point-plan program implementation or application (Barkema et al., 
1998b). 
For successful implementation of a mastitis control program, it is important 
to identify Staph. aureus -infected cows and heifers early, and deal with 
them in such a way that the opportunity for spread of the pathogen in the 
herd is reduced (Zadoks et al., 2002a). This can be done through 
segregation, culling, or treatment. Many herds do not have facilities or 
employees to handle additional groups or individual animals and are not 
willing to cull infected animals (Wilson et al., 1995; Sears, 2002). As a 
result, interest in treatment of Staph. aureus mastitis has reemerged in 
some countries in recent years as shown by several studies on treatment 
of nonlactating heifers and the availability of drugs specifically for treatment 
of subclinical mastitis during lactation (Borm et al., 2005; Deluyker et al., 
2005). 
Some factors were not evaluated in each study but showed a similar 
direction of effect in all studies in which they had been evaluated. A higher 
number of Staph. aureus positive samples before treatment was 
associated with a decreased cure risk (Sol et al., 1994, 1997; Dingwell et 
al., 2003). Similarly, higher colony-forming unit counts in the milk samples 
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were associated with a lower probability of cure (Dingwell et al., 2003; 
Deluyker et al., 2005). When multiple quarters of a cow are infected, cure 
rate is lower at the cow level (Sol et al., 1994; Osteras et al., 1999; Janosi 
et al., 2001) and at the quarter level (Barkema et al., 2006). 
The knowledge about involved cow factors can be used to predict the 
probability of cure and could be used to select candidates for mastitis 
treatment as opposed to culling is vastly underused by pharmaceutical 
companies, farmers, and veterinarians. 
The number of quarters infected with Staph. aureus is an important 
predictor of cow-level cure during the dry period, with more infected 
quarters resulting in a lower risk of cure at cow and quarter level (Sol et al., 
1994; Osteras et al., 1999; Janosi et al., 2001). In addition, if not all quarters 
of a cow are cured, the uninfected quarters of that animal are at higher risk 
of (re)infection with the pathogen, probably as a result of self-reinfection; 
that is, reinfection of cured quarters by non-cured quarters within the same 
cow (Zadoks et al., 2001). Quarter location was also a consistent factor, 
with hind quarters showing significantly lower cure rates. Generally, hind 
quarters have higher infection risks. One could speculate that the larger 
volume of hind quarters relative to front quarters makes it a factor affecting 
cure (Barkema et al., 2006). 
Increasing parity was associated with lower cure risk in virtually all studies. 
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Pyörälä and Pyörälä (1998) report 57% cure of heifers with clinical Staph. 
aureus mastitis and 27% cure of older animals when treated with penicillin 
G. For penicillin-susceptible isolates, Ziv and Storper (1985) report 80% 
cure at quarter level in heifers and 50% or less cure in older animals after 
4-d treatment of subclinical mastitis. Taponen et al. (2003b) report 92 and 
67. Indeed higher parity and higher SCC is also associated with a lower 
chance of cure (Ziv and Storper, 1985; Pyörälä and Pyörälä, 1998; 
Taponen et al., 2003b). 
 
1.2.4.Staphylococcus aureus therapy 
 
An obvious reason for failure to cure after antibiotic treatment is resistance 
of the infecting Staph. aureus strain to the antibiotic treatment. The choice 
of treatment should be based on knowledge of the antimicrobial 
susceptibility of the Staph. aureus strain (Barkema et al., 2006). When 
treating subclinical infections, treatment can be postponed until results of 
cow-level susceptibility testing are available. For clinical mastitis, treatment 
choices can be based on herd-level knowledge of the susceptibility 
patterns of predominant strains. Such herd-level knowledge can be 
obtained through susceptibility testing of clinical isolates after treatment 
has been initiated. Results from previous clinical cases can then be used 
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to develop a herd-level treatment plan for subsequent clinical cases 
(Roberson, 2003). 
Extended therapy is generally associated with a higher probability of cure, 
for example 5- or 8-d treatment of mastitis, as opposed to the 2- or 3-d 
treatment that is usual for clinical mastitis, has been investigated in several 
studies. Field trials with commercial antimicrobial products showed higher 
proportions of cure when using extend treatment, both for treatment of 
clinical and subclinical Staph. aureus mastitis (Owens et al., 1997; Sol et 
al., 2000; Gillespie et al., 2002; Deluyker et al., 2005). Extended therapy 
does not always result in success as shown by an Australian study of 
lactational treatment of subclinical mastitis. The probability of cure in 
animals that received 6-d treatment (3 intramammary treatments with 200 
mg of cloxacillin at 48-h intervals, combined with 3 parenteral erythromycin 
treatments at 24-h intervals) did not differ from the probability of cure in 
animals that did not receive any treatment (Shephard et al., 2000). 
Benefits of extended therapy protocols, such as higher proportions of cure, 
resulting in decreasing SCC, less risk of transmission, and improved 
marketability of milk, must be weighed against several drawbacks, 
including the price of the antibiotic, loss of milk due to withdrawal, increased 
risk for residues in the milk, and the potential of infecting the cow through 
repeated infusions via the teat canal (Janosi et al., 2001; Poelarends et al., 
2001; Gillespie et al., 2002; Swinkels et al., 2005). The incidence of new 
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IMI with Escherichia coli or Klebsiella spp. increased considerably with an 
increasing duration of intramammary treatment (Gillespie et al., 2002). 
Some studies aimed to compare the efficacy of local and systemic antibiotic 
treatment (Sérieys et al., 2005) do not describe a comparison of different 
routes of administration, but rather different active compounds that happen 
to be administered via different ways (Pyörälä, 2005). When comparing 
parenteral and local treatment, it is important to ascertain that therapeutic 
concentrations are reached in the udder with both treatments (Pyörälä, 
2005). The total amount of antibiotics used for treatment may be larger for 
parenteral treatment than for intramammary treatment (Hillerton and Kliem, 
2002), which could affect the economic benefit or the risk of development 
of antimicrobial resistance. The contagious nature of Staph. aureus should 
be considered when evaluating the effect of treatment of infected quarters 
and when evaluating treatment programs in herds. At the quarter level, the 
effect of treatment may be underestimated if contagious transmission 
results in reinfection of a cured quarter. In herds with high prevalence, 
infection pressure will be high, resulting in a higher proportion of 
reinfections or apparent failures to cure. This is particularly true when so-
called ‘Staph pens’ are used to house all cows that have ever been infected 
with Staph. aureus. In some situations, strain typing can help to distinguish 
cured followed by reinfection with a different strain from non-cured. 
However, strain typing cannot distinguish between non-cured and cured 
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followed by reinfection with the same strain. The predominance of a 
contagious strain of Staph. aureus in most herds may make the 
differentiation between cure and non-cured impossible. Statistical methods 
whereby prevalence is used as a covariate may be used to account for 
exposure to other infected cows. However, this may not be feasible in all 
studies. The minimum would be to report herd prevalence of Staph. aureus 
and the housing and management characteristics of the treated cows 
during the full period of the trial. The effect of treatment may also be 
underestimated at the herd level, if prevention of infections in herd mates 
is not taken into consideration as one of the positive effects of treatment 
(Swinkels et al., 2005).  
We believe that conscious selection of cows that have a reasonable 
probability of cure after treatment could contribute to a major improvement 
in management and cure of Staph. aureus mastitis. This process should 
consist of 1) early detection; for example, through monthly screening of 
cow-level SCC, followed by identification of infected quarters using the 
CMT and culture of milk samples from quarters with positive CMT results; 
2) rapid follow up on information from tests; that is, CMT and culture 
immediately following receipt of SCC results by mail or e-mail, low 
turnaround time of milk samples, and prompt communication of results to 
herd managers; 3) access to cow-level data on parity, lactation stage, 
pregnancy status, production level, and mastitis and SCC history; 4) 
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characterization of the Staph. aureus isolates with respect to penicillin 
susceptibility ; 5) a protocol for decision making on the choice and duration 
of treatment (Barkema et al., 2006). For example, a cow with a low chance 
of cure (e.g., less than 30%, or some other threshold that can be 
implemented in the decision process independent of the person following 
the decision-making protocol) is segregated and eventually culled, 
whereas a cow with higher chance of cure is treated. Clearly, cow factors 
such as expected milk production and strain factors such as antimicrobial 
resistance should play a role in the decision-making algorithm, and herd 
level or external factors such as within-herd prevalence, contagiousness, 
and price of milk, cull cows, and replacement heifers must be weighed. 
Because of the contagious nature of Staph. aureus mastitis, cure of 
subclinically infected animals will also result in reduced incidence and 
prevalence of Staph. aureus in the herd. Thus, establishment of 
intramammary infection by Staph. aureus adhesion to mucosal surfaces 
may be a significant step in establishing persistent infections, and biofilm 
production might be an asset. 
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1.3.Coagulase Negative Staphylococci  
 
Coagulase Negative Staphylococci (CNS) species are the predominant 
group of bacteria in mastitis prevalence studies worldwide (Sampinon et 
al., 2011). Several studies have been assessed to develop and evaluate 
methods for identification of CNS at species level, but the diagnostic 
relevance of species identification in dairy practice is yet to be determined 
(Sampimon et al., 2009b; Zadoks and Watts, 2009). Identification at 
species level would be important if it reflects differences in virulence 
characteristics or epidemiology, e.g. in somatic cell count increase 
(Sampimon et al., 2009a), persistence (Taponen et al., 2006) or 
transmissibility, and if it has impact on management and treatment 
decisions, e.g. choice of therapy based on resistance patterns.  
Piessens et al. (2011), reported how many different CNS species could be 
found in cow environment at farm level (Figure n.2), taking sample from 
stall air, slatted floors, sawdust from cubicles, and sawdust stock from 6 
different farms. CNS were isolated from 75 of 78 (96.2%) floor samples, 
from 77 of 78 (98.7%) air samples, from 65 of 73 (89.0%) used bedding 
samples, and from 50 of 73 (68.5%) bedding stock samples. The CNS 
species predominant in the environment over all herds were Staph. 
equorum (19.0% of the isolates), Staph. sciuri (17.9%), and Staph. 
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haemolyticus (16.6%). The species Staph. cohnii (5.7%), Staph. simulans 
(5.3%), Staph. xylosus (3.1%), Staph. devriesei (2.8%), and Staph. arlettae 
(2.5%) were also isolated in the environment of each herd, but less 
frequently.  
Figure n. 2 - Distribution of CNS isolates from environmental samples (stall 
air, slatted floors, sawdust from cubicles, and sawdust stock) (Piessens et al., 
2011) 
 
CNS IMI in dairy cows are commonly caused by Staph. chromogenes, 
Staph. simulans, Staph. xylosus, Staph. epidermidis, Staph. hyicus, and 
Staph. haemolyticus (Thorberg et al., 2009; Park et al., 2011).  
Piessens et al. (2011) found the same results too; in effect the first 4 CNS 
species isolate from IMI in cows were Staph. chromogenes, Staph. 
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haemolyticus, Staph. simulans and Staph. epidermidis confirming what 
was found in references. 
Figure n.3 - Distribution of detected IMI caused by CNS species in monthly 
sampled cows in 6 herds (Piessens et al., 2011). 
 
It appears that the effects on mammary gland health with CNS IMI are 
species dependent. The Staphylococcus species chromogenes, simulans, 
and xylosus are the most persistent in terms of mean duration of IMI, and 
Staph. chromogenes had the greatest ratio of persistent to nonpersistent 
IMI (Supré et al., 2011). 
Historically, CNS IMI have received less attention compared with IMI 
caused by major pathogens such as Staph. aureus, streptococci, and 
coliforms. One of these reasons is that CNS IMI most often remain 
subclinical and, generally, lead to only mild to moderate SCC increase 
compared with IMI caused by major mastitis pathogens (Djabri et al., 2002; 
Sampimon et al., 2010; Supré et al., 2011). With the gradually increasing 
control of IMI caused by major mastitis pathogens, however, recognition of 
the importance of CNS IMI and of their potential effect on udder health is 
rising (Dufour et al., 2012). 
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The difference between IMI and transient colonization of CNS is not always 
clear, as a milk culture might test positive for a microorganism due to 
clinical or subclinical mastitis (Harmon, 1994) or because of transient 
colonization of the teat canal and teat cistern with no major involvement of 
udder parenchyma (Persson et al., 1995; Taponen et al., 2007). Some 
studies have defined a minimum number of colony forming units per ml 
(cfu/mL), as criterion for discrimination between IMI and transient 
colonization (Djabri et al., 2002; Pitkala et al., 2004; Østerås et al., 2006). 
Others Authors have used a combination of repeated positive diagnoses 
for CNS (Davidson et al., 1992; Taponen et al., 2007; Thorberg et al., 2009) 
or Staph. aureus (Zadoks et al., 2002a) combined with threshold values of 
cfu/ml for the differentiation. Other studies for CNS used a combination of 
threshold bacterial count values and persistency in monthly milk samples 
to differentiate between IMI and incidental isolation events (Zadoks et al., 
2002a). 
Humans and dairy cattle may share CNS infections, especially for Staph. 
epidermidis infections. It is difficult to demonstrate the direction of 
interspecies transmission, but it has been suggested that Staph. 
epidermidis is more likely spread from humans to dairy cattle than vice 
versa (Thorberg et al., 2006). In some herds, CNS infections cause herd 
problems with high bulk tank milk SCC (BTMSCC), a high incidence of 
clinical cases, or both (Harmon and Langlois, 1989; Davidson et al., 1992).  
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1.3.1.CNS mastitis 
 
Clinical and subclinical mastitis caused by CNS are common in many 
intensive dairy production systems around the world. Normally, very limited 
data are available on differences in the epidemiology of different CNS 
species, such as in the persistency of IMI. In one study in an experimental 
herd, Staph. chromogenes IMI were considered as being more persistent 
than IMI with other CNS species during lactation (Harmon and Langlois, 
1989). Conversely, Aarestrup et al. (1995) reported that the prevalence of 
Staph. chromogenes declined very rapidly 1 month after calving among 
dairy heifers from different herds and that Staph. simulans was involved in 
persistent IMI. Overall, the spontaneous elimination rate of CNS in the 
udder has been reported to be both higher and lower compared with other 
udder pathogens (Thorberg et al., 2009). In recent years, the prevalence 
of CNS-associated IMI has increased in several areas (Pyörälä and 
Taponen 2009). Some consider CNS as an emerging mastitis pathogen 
(Pyörälä and Taponen, 2009). With regard to a mastitis diagnosis, CNS are 
not usually identified at the species level and are treated as a uniform 
group. 
However, as wrote above, recent studies have indicated that some species 
might be more clinically relevant than others (Supré et al., 2011; Piessens 
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et al., 2011, 2012). 
Mastitis associated with CNS IMI are often subclinical or mild, during 
lactation, CNS infections may result in an increased milk SCC, which 
decreases the milk quality and lead to significant economic losses.  
 
1.3.2.Associations between CNS IMI, SCC and Daily Milk Yield 
 
Conflicting results have been presented concerning the association 
between CNS IMI and milk yield. Early studies described no (Eberhart et 
al., 1982) or a negative correlation (Timms and Schultz, 1987) between 
such infections and milk production. Later studies found higher milk 
production in cows with CNS IMI than in healthy cows in 2 large US studies 
(Wilson et al., 1997; Schukken et al., 2009a). A study on associations 
between milk production and clinical mastitis, reported that multiparous 
cows affected by clinical CNS mastitis had higher milk production before 
the onset of mastitis than did healthy cows (Gröhn et al., 2004). One reason 
for the variable results may be related to lack in CNS species identification. 
However, no many studies have investigated possible differences between 
different CNS species on the associations with SCC or milk production. 
Thorberg et al. (2009) investigated the epidemiology of different CNS 
35 
 
species in Swedish dairy herds with problems caused by subclinical CNS 
mastitis. The hypotheses were that CNS species would differ in their ability 
to induce persistent IMI, and that CNS species would differ in their 
association with milk production and SCC. In this study, 544 cows were 
sampled twice and 380 of those, with complete milk records, belonged to 
cows categorized as healthy, or with subclinical mastitis caused by Staph. 
chromogenes, Staph. epidermidis, and Staph. simulans. 
Looking at the results of this trial cows with non-persistent Staph. simulans 
IMI had significantly lower milk production than healthy cows or cows with 
persistent Staph. chromogenes, Staph. epidermidis, or Staph. simulans 
IMI. Cows with nonpersistent subclinical mastitis caused by Staph. 
epidermidis had significantly lower production than cows with persistent 
Staph. chromogenes or Staph. simulans mastitis. When comparing all 
cows with non-persistent or persistent subclinical mastitis, significant (P < 
0.01) higher milk production was observed among persistently infected 
cows. Cows with non-persistent subclinical mastitis had significantly (P < 
0.01) lower production than healthy cows. Composite SCC did not differ 
between cows with non-persistent and persistent subclinical mastitis. 
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1.3.3.Associations between CNS IMI, lactation number and 
lactation stage 
 
The distribution between lactation numbers differed between CNS species. 
Staph. epidermidis was more common found in older cows with subclinical 
mastitis than in first-lactation cows with subclinical mastitis (P < 0.001), 
whereas opposite was for Staph. chromogenes and Staph. simulans that 
are evenly distributed between young and older cows with subclinical 
mastitis. However, limited information are available on how CNS problems 
develop in a herd and how the infection spreads and persists. 
Consequently, it is difficult to give advice on mastitis control in these herds 
(Thorberg et al., 2009). Little is also known regarding the importance of 
cow factors, such as lactation stage and lactation number, on the 
occurrence of CNS IMI. Some reports in the past state that the early-
lactation cow is more susceptible to CNS IMI than cows in later stages of 
lactation (Harmon and Langlois, 1989), whereas other studies state that 
most CNS IMI occur at the end of the lactation period (Davidson et al., 
1992). According to Oliver and Jayarao (1997), there is a trend for the peak 
prevalence of CNS to occur during the transition period, for many CNS IMI 
to be eliminated around calving, and for the prevalence to decline during 
lactation. Moreover, CNS IMI has been reported to be more prevalent in 
primiparous cows than in multiparous cows (Matthews et al., 1992; Oliver 
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and Jayarao, 1997). 
 
1.3.4.CNS therapy 
 
Not many studies about mastitis antimicrobial therapy have been published 
that specifically report results for quarters infected by CNS compared to 
other bacteria. Based on available reports, mastitis caused by CNS seems 
to respond well to antimicrobial treatment. Bacteriological cure ranges from 
80% to 90% (Pyörälä and Pyörälä, 1998; McDougall, 1998; Waage et al., 
2000; Taponen et al., 2003a, 2006). In all these studies, except in the study 
carried out in New Zealand (McDougall, 1998), penicillin G was used in the 
treatment and isolates were shown to be susceptible to penicillin in vitro. 
Elimination rates for mastitis caused by penicillin-resistant CNS have been 
reported to be about 20% lower than those for mastitis caused by penicillin-
susceptible CNS (Pyörälä and Pyörälä, 1998). It is known from Staph. 
aureus mastitis that infections caused by penicillin-resistant isolates may 
not be cured even if the isolate is susceptible in vitro to the antimicrobial 
drug used for treatment (Sol et al., 2000; Taponen et al., 2003b). Cows with 
higher parity have significantly lower tendency to cure (Pyörälä and 
Pyörälä, 1998; Deluyker et al., 2005). For all the trials took in care the 
treatment duration varied from 2 to 4 days. 
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1.4.Biofilm 
 
It was not until the 1990s that biofilms were investigated in relation to 
chronic infections. Since then, biofilm-related infections by gram-positive 
bacteria had been recognized in human medicine for, particularly, Staph. 
epidermidis and Staph. aureus (many types of nosocomial infections), E. 
coli (bacterial prostatitis, biliary tract infection), and Streptococcus spp. 
(dental caries, periodontitis, endocarditis, meningitis, pneumonia) (Donlan 
and Costerton, 2002). Many of these bacterial species are also major 
pathogens involved in bovine mastitis, and thus the difficulties of treating 
recurrent infections might be related to the ability of pathogens to form 
biofilms. As reviewed by Melchior et al. (2006c), recurrent infections are 
often attributed to biofilm growth of bacteria, where biofilm formation is 
accompanied by significant genetic and subsequent physiological changes 
in the microorganisms resulting in the loss of susceptibility to virtually all 
classes of antibiotics. In a biofilm, microbes exhibit enhanced resistance to 
antimicrobial agents, where the mechanisms of resistance is not 
necessarily genetic, by acquiring resistance genes but also depends on the 
multicellular strategies used by the bacteria within the biofilm (Stewart and 
Costerton, 2001). Bacteria coordinate their activities to enhance their ability 
to survive in a specific environment. This coordinated behavior is acquired 
by cell-to-cell communication, or quorum sensing, where bacteria secrete 
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molecules that activate signal transduction systems, leading to the 
expression of genes necessary for the survival in a certain environment 
(Miller and Bassler, 2001). 
In most natural environments, microorganisms try to adhere to available 
surfaces. Hence, the free-swimming (or planktonic) cells can be viewed as 
a mechanism of spreading from one surface to another. Following initial 
attachment of cells to a surface, surface motility and binary division result 
in an aggregation of attached cells (Stoodley et al., 2002). These primary 
cell aggregates produce exopolysaccharides to facilitate clumping. Thus, 
the initial phase of biofilm formation involves two stages: the first stage 
comprises attachment of cells to a surface, facilitated by cell wall 
associated adhesins, which are products of various genes (Mack, 1999). 
Attachment to native polymeric surfaces is increased in the presence of 
matrix proteins including fibronectin, and fibrinogen, whereas laminin 
showed no effect. 
The second stage is characterized by cell multiplication and formation of a 
mature structure consisting of many layers of cells, connected to each by 
extracellular polysaccharides (Yarwood and Schlievert, 2003). Finally, in 
the process of maturation, many staphylococci generate a glycocalyx, a 
slime layer that further protects the biofilm bacteria. The chemical nature 
of these slime layers is still not entirely elucidated, but evidence suggests 
that it consists predominantly of hydrated polysaccharides. The growth 
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potential of any bacterial biofilm is limited by the availability of nutrients to 
the cells within the biofilm and distinct flow-through channels across the 
biofilm aim to maintain perfusion (Stoodley et al., 2002). Other factors that 
are known to control biofilm maturation include internal pH, oxygen 
perfusion, carbon source and osmolarity (Dunne, 2002).  
Some strains of Staph. aureus produce exopolysaccharides. Such 
exopolysaccharides can form capsular or slime layers around single cells. 
Biofilm is also an exopolysaccharide, a slime matrix around multiple layers 
of cells (Vancraeynest et al., 2004) where production of the matrix is under 
polygenomic control (Jefferson, 2004). Capsule has been considered a 
Staph. aureus virulence factor associated with intramammary infections 
(Mamo et al., 1991). Capsular material around the bacterial cell confers 
protection against phagocytes (Watson, 1982), thus protecting the 
pathogen from the host immune response. It has been argued that capsular 
antigens should be part of a Staph. aureus mastitis vaccine to enhance the 
ability of phagocytes to respond to infections with Staph. aureus (Sordelli 
et al., 2000). Biofilm formation may also be a virulence factor associated 
with Staph. aureus mastitis. Some evidence suggests that Staph. aureus 
with gene constructs for biofilm production have increased ability to initiate 
(Baselga et al., 1993) and cause persistent intramammary infections 
(Cucarella et al., 2004). It has been proposed that biofilm, like capsule, 
protects Staph. aureus against phagocytosis and, in addition, it may help 
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Staph. aureus to resist antibiotic therapy (Cucarella et al., 2004). 
Staph. aureus will colonize several sites on a dairy that can contact the 
mammary gland (Fox et al., 1991), and it is assumed that these sites acts 
as fomites of intramammary infection. (Fox and Gay, 1993). Yet evidence 
suggests that the types that colonize extramammary sites are not likely to 
be the same type of Staph. aureus that causes intramammary infection 
(Zadoks et al., 2002a). Given the potential role of exopolysaccharide 
production as a virulence factor for intramammary infection, we 
hypothesized that Staph. aureus that cause intramammary infections are 
more likely to produce biofilm than isolates found on extramammary sites. 
The primary thrust was to test the hypothesis that Staph. aureus isolated 
from milk samples, presumably from cows with intramammary infections, 
were more likely to be biofilm producers than isolates from milking unit 
liners or teat skin. Results from this study would support the hypothesis. 
On a percentage basis, nearly twice and thrice as many milk isolates were 
biofilm positive than isolates from teat skin and milking unit liners, 
respectively. Baselga et al. (1993) suggested that biofilm producing strains 
of Staph. aureus were better able to attach to mammary mucosal surfaces 
and cause infections than strains that did not produce biofilm. Götz (2002) 
indicated that staphylococcal mutants that lacked the ability to produce 
polysaccharide intercellular adhesive were less likely to cause disease 
than their corresponding wild types. Biofilms are a structured community of 
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bacterial cells enclosed in a self-produced polymeric matrix and adherent 
to an inert or living surface (Costerton et al., 1999). This can constitute a 
protected mode of growth that allows survival of bacteria in a hostile 
environment, particularly in high shear environments (i.e., rapidly flowing 
milieus). When biofilms are formed in low shear environments, they are 
generally more sensitive to mechanical breakage. Biofilm-associated 
bacteria shows an innate resistance to antibiotics, disinfectants and 
clearance by host defense mechanisms. 
It may be surprising that more isolates from milking unit liners were not 
biofilm producers because biofilm production seems to be an important 
virulence factor for staphylococcal infections associated with indwelling 
catheters, such as infections with Staph. epidermidis in humans (Götz, 
2002). However, milking unit liners are vigorously washed and sanitized at 
least twice daily, often more frequently. Perhaps the frequent flushing of 
milking unit liners with a detergent followed by halide sanitization prevents 
the establishment of Staph. aureus colonization. Thus there may be no 
selective advantage of a biofilm positive Staph. aureus to associate with a 
milking unit liner as compared to a biofilm negative isolate. This might also 
suggest that any Staph. aureus associated with milking unit liners are 
transient colonizers of that liner. In accordance with that concept, earlier 
studies showed liner isolates to be equally likely to belong to milk or teat 
skin associated strains of Staph. aureus (Zadoks et al., 2002a).  
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1.4.1.Biofilm resistance to antimicrobial agents 
 
Several in vitro studies have shown that bacteria growing in a biofilm can 
become 10–1000 times more resistant to the effects of antimicrobial agents 
as compared to planktonic growing bacteria of the same strain (Amorena 
et al., 1999; Ceri et al., 1999; Conley et al., 2003; Mah and O’Toole, 2001; 
Olson et al., 2002). Several mechanisms are known to be responsible for 
resistance of biofilms to antimicrobial agents, including: (1) delayed 
penetration of the antimicrobial agents through the biofilm matrix; (2) 
altered growth rate of biofilm organisms; (3) physiological changes due to 
the biofilm mode of growth, including ‘‘persister’’ cells. 
The exopolysaccharides forming the biofilm protect bacteria from 
components of the host immune system. Extracellular slime produced by 
Staph. epidermidis protected cells from the phagocytic activity of 
macrophages and against opsonins as well as reactive oxygen species in 
polymorphonuclear leukocytes (Johnson et al., 1986; Yasuda et al., 1994). 
Likewise, a decreased bactericidal activity of neutrophils was observed 
against slime producing Staph. aureus strains (Barrio et al., 2000). 
The production of an exopolysaccharide matrix is one of the distinguishing 
characteristics of biofilms. This matrix impairs the access of antibiotics to 
the bacterial cells (Stewart, 1996). Either a reaction of the compound with, 
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or its adsorption to the components of the biofilm matrix, can limit the 
transport of an antimicrobial agent within the biofilm. Despite the 
emergence of CNS as pathogens, the knowledge regarding their virulence 
and associated mechanisms is limited, but biofilm formation has been 
proposed as an important virulence factor of CNS, especially with regard 
to the persistence of CNS IMI (Simojoki et al., 2012).  
Increasing evidence suggests that antibiotics are not only less effective 
against bacterial biofilms, but also may stimulate the biofilm formation. For 
three classes of antibiotics, including tetracyclines, quinopristine-
dalfopristins and erythromycin, stimulation of the expression of the ica 
genes in Staph. epidermidis has been shown, as mentioned above. 
Induction of these genes by antibiotics promotes the adherence of bacteria 
to biological surfaces and stimulates the formation of biofilms. Subinhibitory 
concentrations of antibiotics can also influence the expression of important 
bacterial virulence factors such as other adhesion molecules or toxins 
(Rachid et al., 2000). 
 
1.4.2.Biofilms and mastitis 
 
Adherence of mastitis pathogens has been investigated in various in vitro 
and in vivo studies (Aguilar and Iturralde, 2001; Almeida et al., 1999; 
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Almeida and Oliver, 2001; Amorena et al., 1990; Hensen et al., 2000a, b). 
Microscopic examination of Staph. aureus in mammary tissue in acute and 
chronic infections showed that the bacteria are mainly located in clusters 
within the alveoli and lactiferous ducts in association with the epithelial cells 
and invaded in the interstitial tissue (Hensen et al., 2000a). These bacterial 
clusters appear approximately 24 h after exposure to the pathogen along 
with the establishment of the intramammary infection. 
The presence of the ica locus among Staph. aureus mastitis isolates was 
recently investigated by Vasudevan et al. (2003). All 35 isolates tested 
possessed the ica locus, but not all isolates were positive with the Congo 
red agar or the biofilm assay test. This indicates that there is a high 
prevalence of the ica genes among Staph. aureus mastitis isolates. 
In mastitis the phenomenon of phase variation and its simultaneous 
transition, from subclinical to clinical infection (and vice versa), is well 
known. Physiological changes in the bovine udder, which most profoundly 
take place in the transition period, seem to cause changes also in the 
bacterial gene expression promoting the up-regulation of virulence genes 
and the transformation from the defensive biofilm growth of pathogens into 
a phase to the offensive growth and distribution of phase of bacteria, 
resulting in inflammation and clinical signs of disease. 
Investigations directed to the SCC pattern during mastitis infections show 
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a relation between (subclinical) infection, rise in SCC and the appearance 
of bacteria in milk (De Haas et al., 2002; Shoshani et al., 2000). In light of 
the present knowledge it is assumed that the phase variation merely 
reflects the dynamics of bacterial biofilms; the exact nature of the stimuli 
activating biofilms, however, needs to be elucidated. 
 
1.5.Mastitis vaccination 
 
The development of effective non-antibiotic methods in control of 
staphylococcal mastitis and reducing somatic cell count is extremely 
desirable, leading to reduced costs, improved animal health and milk 
quality, increased dairy profitability and increased food safety. It is thus 
important to develop a vaccine that would prevent such infections and 
reduce the need for the use of antibiotic. 
Looking on the vaccine available for Staph. aureus mastitis prevention, two 
commercial products are available, Lysigin® (Boehringer Ingelheim 
Vetmedica, Inc) and Startvac® (Hipra, Inc., Spain). In the past some trial 
have shown limited efficacy under field conditions. Describing the 
possibility to use vaccination in combination with treatment Barkema et al. 
(2006) find that the results are encouraging, none of these studies report a 
significant positive effect of vaccination on treatment results.  
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1.5.1.Mastitis vaccination in field trial 
 
In some cases, the power of the study may have been a limiting factor; for 
example, when only 12 cows (respectively, 7 and 5 per treatment arm) 
were enrolled in the vaccination trial (Luby and Middleton, 2005). In a 22-
cow trial in Korea, administration of an autogenous toxoid-bacterin to 
lactating cows with Staph. aureus mastitis resulted in 27% cure of quarters 
in the vaccinated group, which was significantly higher than the 5% cure 
observed in the control group. Vaccination also resulted in a significant 
decrease of SCC (Hwang et al., 2000) but vaccination was not combined 
with antimicrobial therapy in this treatment trial. Response to vaccination 
may be strain-specific, which could result in farm-specific or regional 
differences in vaccine efficacy (Guidry et al., 1998). 
Leitner and colleague (2001) worked on MASTIVACS, This vaccine, upon 
administration to mice elicited high levels of IgG-specific antibodies and 
exhibited highly significant protection against challenge with Staph. aureus 
strains, either homologous or heterologous, in a mouse model. They 
looked on efficacy of the new vaccine in controlled experiments with dairy 
cows. Looking the results that they found and taking care knowledge as 
the pathogenicity of one bacterial strain could be evaluated according to 
the degree of infection, as indicated by secretion of the bacteria and by the 
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SCC, highly significant differences were found between the vaccinated and 
the unvaccinated (control) cows: whereas 19 out of 21 challenged quarters 
of the control group were infected and developed continuous infection, only 
6 out of 17 challenged quarters of the immunized cows were infected. 
Moreover, a comparison between the SCC in the infected quarters of the 
immunized cows and that of the control cows revealed that the immunized 
cows had normal values (100 X 103 ) whereas the control cows showed 
elevated counts (540 X 103 ), indicating a state of inflammation. During the 
trial, neutrophils increased in number and proportion soon after the 
inoculation and were the main cell type in all challenged quarters. These 
findings are consistent with typical acute mastitis (Burvenich et al., 1995). 
However, leukocytes that were identified by LM as neutrophils and were 
gated as PMN by the FACS, received significantly less labeling by the mAb 
G1 in the control cows than in the vaccinated ones. These results are in 
agreement with those previously reported for acute mammary infection by 
E. coli and Staph. aureus (Leitner et al., 2000). This aspect was not 
observed in the vaccinated cows. They could hypothesize that the vaccine 
might protect not only against the strains it comprises, but also against a 
large variety of other pathogenic Staph. aureus strains. However, this 
hypothesis needs to be evaluated in a large-scale field trial. In conclusion, 
the vaccine used in this experiment proved to be safe: it provided about 
70% protection from Staph. aureus infection and complete protection from 
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inflammatory reactions as expressed by the SCC (Leitner et al., 2003). 
The first study step for Startvac® was to analyze an extracellular 
component from Staph aureus which we refer to as slime associated 
antigenic complex (SAAC), and to investigate the role of SAAC-specific 
antibody production in protection from Staph. aureus bovine mastitis. The 
SAAC-specific antigen is a poly-saccharide composed mostly of neutral 
sugars (glucose and galactose) and 6.1% (w/w) of amino sugars 
(glucosamine and galactosamine). 
Twelve primiparous pregnant cows were randomly assigned to one of the 
three groups: Group 1 was vaccinated with a Staph. aureus bacterin with 
very limited SAAC content; Group 2 received a Staph. aureus bacterin with 
high SAAC content and Group 3 served as unvaccinated controls. In the 
present study, they analyzed an extracellular component from Staph. 
aureus, referred to as SAAC, comprising 41.99% protein and 57.53% 
polysaccharide (w/w), in relation to the slime producing phenotype and the 
biofilm formation ability. We observed that cows immunized with a greater 
amount of SAAC associated with the Staph. aureus bacterin (Group 2) 
triggered the highest SAAC-specific antibody levels in serum after 
vaccination (total IgG, IgG1 and IgG2). Moreover, the SAAC-specific total 
IgG concentration in milk in Group 2 was also significantly higher than 
Group 3 cows on the day of the challenge (day 71 post-vaccination), 
although there was no evidence of significant differences between groups 
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in the IgG1 or IgG2 isotypes levels in milk. The production of SAAC-specific 
total IgG antibodies in milk of control animals (Group 3) after challenge, 
suggests that strong biofilm bacteria in vivo express SAAC during the 
mammary gland experimental infection (Prefaneta et al., 2010). They 
suggest that SAAC-specific antibody production in immunized animals 
could be involved in clearance of bacteria and clinical signs reduction after 
Staph. aureus IMI in dairy cows. In this way, bacterins from strong biofilm-
producing bacteria are proposed as a cost-efficient vaccine design against 
bovine mastitis. This information may be relevant for developing more 
efficacious commercial staphylococcal vaccines based on bacterins 
surrounded by their own biofilm matrix containing SAAC (Prefaneta et al., 
2010). 
As mostly studied in Staph. aureus and to some degree in Staph. 
epidermidis, quorum sensing is achieved by activating the accessory gene 
regulator (agr) that results in the production of a regulatory mRNA molecule 
termed RNAIII. In the presence of RNAIII, multiple toxin genes are 
activated, resulting in devastating diseases (Lowy, 1998; Novick and 
Geisinger, 2008). It was discovered that a peptide, termed RNAIII inhibiting 
Peptide (RIP), inhibits the agr and thus inhibits the production of RNAIII. 
RIP has been shown to prevent numerous types of Staph. aureus and 
Staph. epidermidis infections in vivo, including medical device associated 
infections (tested against MRSA, MRSE, VISA and VISE) (Anguita-Alonso 
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et al., 2007; Balaban et al., 2000, 2003, 2004, 2005, 2007; Cirioni et al., 
2003, 2006, 2007; Dell’Acqua et al., 2004; Domenico et al., 2004; 
Giacometti et al., 2003, 2005; Simonetti et al., 2008; Vieira-da-Motta et al., 
2001) and was shown to enhance the antibacterial effect of antibiotics. 
These findings indicate that RIP can suppress virulence of any 
staphylococcal strain so far tested and is synergistic to antibiotics (Lopez-
Leban et al., 2010). 
 
1.5.2. Target of RNAIII Activating Protein (TRAP) 
 
TRAP was initially discovered as a protein whose phosphorylation is 
suppressed by RIP (Balaban et al., 2001) and it is a membrane-associated 
167 AA residue protein that is constitutively expressed and is highly 
conserved among staphylococci. TRAP is a histidine autokinase that 
modulates stress response and protects DNA from environmental damage. 
So that when TRAP is inhibited by mutagenesis, agr undergoes deleterious 
mutations and is thus inactivated (Kiran and Balaban, 2009). 
Consequently, multiple agr-regulated toxins would not be produced and the 
bacteria would be non-pathogenic (Lowy, 1998). Indeed, antibodies to 
TRAP have been shown to suppress exotoxin production by Staph. aureus 
in vitro (Vieira-da-Motta et al., 2001). In summary, TRAP protects bacteria 
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from stress, is constitutively expressed, is membrane-associated and is 
available to anti- body interaction, and is conserved among staphylococci. 
TRAP may thus be a useful broad vaccine to protect from infection caused 
by various types of staphylococci. 
More studies are needed before combining lactational therapy with 
vaccination can be advised in the treatment of subclinical Staph. aureus 
mastitis during lactation. 
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2.MATERIALS AND METHODS 
 
2.1.Herds 
 
To evaluate vaccine efficacy we studied infection dynamics in two herds 
with a total of approximately 450 dairy cows milking at any point in time. 
The herds had a known prevalence of Staph. aureus of at least 5% of cows 
and a bulk milk somatic cell count (SCC) between 250,000 scc/ml and 
400,000 scc/ml. The trial started in May 2011, sampling, vaccinating and 
collecting data on the farms until February 2013 for farm A for a total of 21 
months and October 2012 for farm B for a total of 18 months.  
Farm A, maintained an average of 130 Holstein milking cows housed in 
free stall barns with deep-bedded cubicles with straw. Farm B maintained 
an average of 320 Holstein milking cows housed in free stall barns with 
deep-bedded cubicles with sawdust. On both farms, cows that were close 
to calving were moved to a loose housing maternity pen bedded with straw. 
Animals were housed for the first week of lactation in a large loose housing 
pen with straw. After one week of lactation, cows were moved to free stall 
facilities. All groups of cows in both dairies were fed a balanced TMR in 
feed alleys with headlocks that allowed restraint of cows for examination, 
administration of treatments, medications and vaccinations. No 
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segregation of cows based on IMI status or SCC level was done on either 
farm. 
 
2.2.Milking equipment evaluation 
 
On Farm A cows were milked in a double-12 parallel parlor 2 times/d, while 
Farm B had a double-15 herringbone parlor and cows were also milked 2 
times/d. On the farms, milking equipment was evaluated twice during the 
study period by technicians of the Regional Breeding Association using a 
complete ISO 6690:2007 defined evaluation (ISO, 2007). Equipment 
evaluation took place at the beginning and at approximately one year into 
the study. No important concerns with milking equipment were identified on 
either farm.  
 
2.3.Cow data  
 
Cow data on calving, parity, reproduction (AI dates, pregnancy), clinical 
disease (including retained placenta, endometritis, metritis, lameness, 
clinical mastitis and metabolic diseases such as ketosis, abortium and 
displaced abomasum) and culling was collected for all cows in the herd. 
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Dur i ng  the  t r i a l ,  I t a l i an  DH IA  t es t i ng  i n  bo th  he rds  was  
done  mon th l y  fo r  m i l k  p roduc t i on ,  fa t ,  p ro te i n  and  SCC.  
Cow data were collected using a computerized herd record keeping system 
(Dairy Comp 305, Valley Agricultural Software, Tulare, CA) was used. 
 
2.4.Vaccination  
 
Vaccination took place according to label directions in the dry period and 
early lactation. The 1st vaccination was at 45 days (+ 3 days) before the 
expected parturition date, the 2nd vaccination at 35 days thereafter (+ 3 
days), corresponding to 10 days before the expected parturition date and 
3rd vaccination was at 52 DIM (+ 3 days). No placebo or sham vaccination 
was used in this trial. Cows going through a second dry period during the 
study were kept in the same treatment group (vaccinated or control). At the 
start of the trial, all cows that were due to calve were vaccinated until 
approximately 50% of cows in the milking herd were vaccinated (~6 
months). At that point in time when 50% vaccination coverage was reached, 
cows were randomly assigned to be vaccinated or left as controls. Trained 
farm personnel on farm A and the herd veterinarian on farm B performed 
all vaccinations. Assignment of vaccination was done using the European 
cow registration number whereby even numbered cows were vaccinated 
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and odd numbered cows were kept as controls. Cows were identified in 
each farm using unique farm-specific ear tags. There was no logical 
relationship between the on-farm ear tag number and the official 13-digit 
European cow registration number. 
 
2.5.Milk sampling 
 
Monthly quarter sampling of all lactating cows in herds was done during 
the trial period. In addition, quarters were sampled when a case of clinical 
mastitis occurred, when cows were dried off, upon calving and culling. 
Before sampling teat ends were carefully cleaned and disinfection with 
chlorhexidine. First streams of foremilk were discharged, and then 
approximately 10mL of milk was collected aseptically from each teat into 
sterile vials. Samples were stored at 4°C until bacteriological assays and 
SCC tests were performed.  
 
2.6.Bacteriological analysis 
 
Bacteriological cultures were performed according to standards of the 
National Mastitis Council (NMC, 1999). Ten microliters of each milk sample 
were spread on blood agar plates (5% defibrinated sheep blood). Plates 
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were incubated aerobically at 37°C and examined after 24 h. Colonies 
were provisionally identified on the basis of Gram stain, morphology, and 
hemolysis patterns, and the numbers of each colony type was recorded. 
Representative colonies were then sub‐cultured on blood agar plates and 
incubated again at 37°C for 24 h to obtain pure cultures. Catalase and 
coagulase production were tested for gram‐positive cocci. Gram-negative 
isolates were identified using colony morphology, Gram‐staining 
characteristics, oxidase, and biochemical reactions on MacConkey’s agar. 
For plates with Staph. aureus and CNS growth, the number of colonies was 
recorded for each species isolated, and colonies were reisolated and 
frozen for further characterization. 
 
2.7.Definition of infection status 
 
Staph. aureus was considered to cause an IMI if at least one colony (≥100 
cfu/mL) was isolated. For CNS, IMI was defined by the isolation of at least 
two colonies (≥ 200 cfu/mL) from a single sample or ≥100 cfu/mL from a 
clinical sample. When multiple, at least two out of three, consecutive 
samples with >100 cfu/mL of CNS were identified, this was also considered 
an IMI. These definitions are based on the consensus opinion of mastitis 
research workers as published by Dohoo et al. (2011) and Andersen et al. 
(2010). A quarter was defined as uninfected and at risk for a new infection 
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when two consecutive samples were culture negative. An infection was 
considered cured if two consecutive monthly milk samples did not show the 
presence of the causative organism. Milk samples where 3 of more species 
were identified were considered contaminated. All culture results were kept 
from both farm staff and herd veterinarians until the very end of the study. 
When entering or leaving the trial or re‐entering after calving, a single 
negative sample was considered sufficient to be defined as uninfected.  
 
2.8.Statistical analysis 
 
Data were analyzed using the SAS v9.2 system (SAS Institute Inc., Cary, 
NC). Descriptive analysis was done on all important outcome variables and 
covariates. Transformations were used where outcome variables were not 
normally distributed (e.g. SCC and cfu).  
 
 
 
2.8.1.Logistic regression analysis – risk factors for new IMI and 
cure of IMI 
Linear regression models were used for analysis of crude prevalence and 
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incidence of IMI. In these generalized linear models only data were used 
after the 50/50 randomization in the herds had started. Every quarter-month 
at risk of either an incident or prevalent staphylococcal IMI contributed a line of 
data to this analysis. The generalized linear model had the following format: 
Logit(Y) = intercept + mim + lactgroup + herd + vaccination + complex error 
Where, Y is the outcome of interest (incidence or prevalence of Staph. 
aureus and CNS, mim is month in milk, lactgroup is the lactation number of 
the cow grouped into 1, 2 and 3+, herd is herd code and vaccination is 
either vaccinated or control. Complex error is a correlated error term where 
within cow correlation is combined with a random binomial error.  
Duration of infection was estimated with the use of time‐to‐event analysis. 
Kaplan‐Meier estimates of the survivor curves were used for graphical 
representation of the results. Cox‐regression was used for estimating the 
impact of vaccination on the duration of infection. For this analysis, only 
new infections were used that started after the 50/50 randomization in the 
herds had started.  
2.8.2.Modeling infection dynamics 
 
The rate of new infections per day at risk was calculated for vaccinated and 
control cows. The rates were calculated on a monthly basis for the duration of 
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the trial. For evaluation of vaccine efficacy of Staph. aureus and CNS, the 
transmission rate, β, taking exposure into account was calculated and 
compared between vaccinated and control cows. Exposure was based on 
the number of Staph. aureus or CNS shedding quarters at the same time in the 
herd. The modeled relationship was defined as: 
New Staph. aureus/CNS infectionsv/c = β v/c * Sv/c * (Iv+Ic) + covariates. 
Where v/c is vaccinated or control, S is the number of susceptible quarters, 
I is the number of infected quarters and β is the transmission parameter. 
Direct vaccine efficacy for new infections may then be estimated as 1‐( β v / β 
c). 
Similarly, cure of infection was modeled using the following equation:  
Cure Staph. aureus/CNS infectionsv/c = αv/c * Iv/c + covariates. Again, 
direct vaccine efficacy may then be estimated as 1‐ (αv / αc). 
Estimates of α and β were obtained through linear models using Poisson 
regression. The regression model for estimation of β was: 
Ln(nr new infectionsv/c) = β*v/c + covariates + offset. 
Where the offset is given by Ln((Sv/c * (Iv+Ic) )/N). The parameter β can then 
be calculated as exp(β*). For estimation of α, the Poisson regression 
equation was: 
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Ln(nr cured infectionsv/c) = α
*
v/c + covariates + offset. 
Where the offset is given by Ln(Iv/c). The parameter α was then be 
calculated as exp(α*). Population vaccine efficacy was estimated using the 
above parameters α and β, where vaccine efficacy were respectively 
defined as: Vaccine efficacy for new infections = 1 −  
𝛽𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑒𝑑
𝛽𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 , while the 
vaccine efficacy for cure of infections = 1 −  
𝛼𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝛼𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑒𝑑
 . Combining the 
information of parameters α and β into an overall infection reproduction 
ratio provides an unbiased summary parameter on vaccine efficacy. The 
basic reproduction ratio, R0, was defined as R0 = β/α and the resulting 
vaccine efficacy is then calculated as: 1 −  
𝑅0,𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑒𝑑
𝑅0,𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 = 1 −  
𝛽/𝛼𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑒𝑑
𝛽/𝛼𝑐𝑜𝑛𝑡𝑟𝑜𝑙
. The 
variance of R0 may be calculated from the sum of the variance of the 
logarithm of the two components of R0: Var(ln(R0)) = Var(β*) + Var(α*). This 
overall efficacy parameter is expected to provide the best summary of the 
overall impact of vaccination on infection dynamics in a vaccinated 
population (Halloran et al. 2008).  
2.9.Samples size  
 
The study was planned using a design of co-mingling vaccinates and 
controls with one control per vaccinate. Since cow is the unit of vaccination, 
sample size calculations were performed at cow level. Prior data indicated 
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that the new infection rate among controls is approximately 0.15 per 
lactation. This new infection risk of 0.15 includes both Staph. aureus and 
CNS infections. If the true vaccine efficacy is at least 50% then the new 
infection rate for vaccinated cows is 0.075. We needed to study at least 
250 vaccinated cows and 250 control cows to be able to reject the null 
hypothesis that the new infection rates for vaccinated and control cows 
were equal (e f f icacy = 0)  with probability (=power) 0.8. The Type I error 
probability associated with this test of this null hypothesis is 0.05. Because 
of the cow dependency due to co-mingling, we estimated an increased 
sample size by approximately 25% resulting in at least 315 cows per 
treatment arm, resulting in a study size of at least 630 cows in total. 
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3.RESULTS 
 
3.1.Data quality 
 
Data checks and data entry occurred throughout study. Entry into the 
vaccination group was not as fast as expected on farm A as pregnant 
heifers were initially not vaccinated. This was corrected as soon as noted 
in the database. For this reason, the farm reached the 50/50 point a few 
months later and it was decided to keep the herd in the study for a longer 
period compared to farm B. Data quality was checked throughout the study 
and additional information was collected where needed.  
 
3.2.Descriptive statistics 
 
During the entire study, a total of 1.156 lactations in 809 cows were 
identified in both herds. 658 cows (56.92%) were enrolled as controls, 343 
cows (29.67%) were fully vaccinated and 155 cows (13.34%) started the 
vaccination but were not fully vaccinated due to calving date estimation 
errors in pregnancy checking, early pregnancy loss, abortions, early 
calving or end of the study.  
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Since vaccination was initially done on all cows calving into the lactating 
herd, the percentage of cows that were vaccinated increased rapidly in both 
herds. The percentage of vaccinated lactations in each herd throughout the 
trial is shown in Figure 4.  
Figure 4. Percent of lactations that were either vaccinated or control. In herd 
A the 50/50 status was reached in month 11 into the study while in herd B this 
was at 8 month 
 
In herd B, the 50/50 status was reached in month 8 of the study, while in 
herd A this was at 11 months into the study. Given that vaccinations starts 
at approximately 2 months before anticipated calving, the change in 
randomization procedure started in herd B at 6 months after the start of the 
study, while this was 9 months after the start of the study in herd A. 
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3.3.Bacterial culture results 
 
Throughout the study, 39.506 quarter milk samples were taken and used 
for bacterial culture. The results of bacterial culture of all these samples are 
shown in Table 1.  
Table 1. Bacterial results of all samples collected during the trial, monthly 
samples, dry-off, calving, culling and clinical mastitis cases. 
   Farm A  Farm B 
Pathogen N Percent  N Percent 
Staphylococcus aureus 2151 15.6  929 3.8 
CoagulaseNegative 
Staphylococci 937 6.8 
 
1139 4.6 
Str. bovis 0 0.0 
 
50 0.2 
Str. canis 1 0.0  4 0.0 
Str. dysgalactiae 19 0.1  176 0.7 
Str. mitis 14 0.1  36 0.1 
Str. uberis 132 1.0  217 0.9 
Streptococcus spp. 89 0.6  117 0.5 
Corynebacterium spp. 40 0.3  63 0.3 
Enterococcus faecalis 38 0.3  55 0.2 
Lactococcus lactis 11 0.1  70 0.3 
Aerococcus viridans 58 0.4  88 0.4 
Escherichia coli 81 0.6  191 0.8 
Enterobacter spp. 19 0.1  17 0.1 
Other Gram-negatives 52 0.4  36 0.1 
Klebsiella spp. 6 0.0  116 0.5 
Pasteurella spp. 2 0.0  8 0.0 
Proteus spp. 63 0.5  65 0.3 
Prototheca spp. 3 0.0  0 0.0 
Serratia spp. 4 0.0  15 0.1 
Trueperella pyogenes 0 0.0  2 0.0 
Bacilli 5 0.0  26 0.1 
Blind quarters 260 1.9  539 2.1 
Missing/Contaminated 671 2.0  1452 3.5 
Culture negative 9503 69.0  19936 80.5 
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The most commonly isolated pathogens in herd A were Staph. aureus 
2.151 (15.6%) and CNS 937 (6.8%). In contrast, in herd B 1139 CNS 
(4.6%) were more frequently identified then Staph. aureus with 929 (3.8%). 
Culture negative status was observed in 9.503 samples (69%) for farm A 
and in 19.936 samples (80.5%) for farm B. 
A total of 375 clinical cases were identified in the two farms during all the 
trial. Culture results of the clinical cases are shown in Table 2. 
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Table 2. Bacterial culture results of clinical mastitis cases in the two farms. 
   Farm A Farm B 
Pathogen   N Percent N Percent 
S.aureus   38 11.5 37 7.0 
CNS   11 3.3 42 7.9 
S.bovis   0 0.0 4 0.8 
S.canis   0 0.0 2 0.4 
S.dysgalactiae   3 0.9 31 5.8 
S.mitis   0 0.0 7 1.3 
S.uberis   25 7.6 56 10.5 
Streptococcus 
spp.   11 3.3 20 3.8 
Corynebacterium 
spp.   1 0.3 0 0.0 
Enterococcus 
faecalis   5 1.5 5 0.9 
Lactococcus lactis   0 0.0 11 2.1 
Aerococcus 
viridans   0 0.0 2 0.4 
E.coli   23 7.0 80 15.0 
Enterobacter spp.   1 0.3 6 1.1 
Other Gram-
negatives   0 0.0 4 0.8 
Klebsiella spp.   1 0.3 52 9.8 
Pasteurella spp.   0 0.0 0 0.0 
Proteus spp.   1 0.3 2 0.4 
Prototheca   2 0.6 0 0.0 
Serratia spp.   1 0.3 2 0.4 
Trueperella 
pyogenes   0 0.0 1 0.2 
Culture negative   207 62.7 168 31.6 
 
Also for the clinical mastitis the most commonly isolated pathogen in herd 
A were Staph. aureus 38 (11.5%) followed by S. uberis 25 (7.6%) E.coli 23 
(7%) and CNS 11 (3.3%). Differently in herd B, Staph. aureus and CNS 
were not the most commonly isolated pathogen. Infact E. coli 80 (15%), S. 
uberis 56 (10.5%) and Klebsiella spp 52 (9.8%) were more frequently 
68 
 
identified then CNS (7%) and Staph. aureus 929 (3.8%). Culture negative 
status was observed in 207 samples (62.7%) for farm A and in 168 samples 
(31.6%) for farm B. 
Prevalence of Staph. aureus during the course of the study remained more 
or less stable in farm A, ranging from 19.6% at month 1 to 14.8% at month 
22, but reduced dramatically in farm B from 10.5% at month 1to 1.2% at 
month 18. 
In both farms, there was a fairly stable situation with not much change in 
prevalence of CNS IMI, ranging from 5.0% at month 1 to 9.2% at month 22 
for farm A and from 5.1% at month 1 to 4.4% at month 18 for farm B. When 
expressing prevalence by month in lactation, the data indicated a gradually 
increasing difference in prevalence between controls and vaccinates. This 
trend was present for both Staph. aureus and CNS IMI. The least square 
means of the prevalence of infection for Staph. aureus and CNS is shown 
in Figures 5a and 5b. 
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Figure 5a. Prevalence of Staph. aureus (intramammary infection in all 
quarters during the course of the study in vaccinated ( ▲ ) and control (― ● 
―) cows. Only cows that were eventually fully vaccinated are included in this 
analysis.  
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Figure 5b. Prevalence of CNS (intramammary infection in all quarters during 
the course of the study in vaccinated ( ▲ ) and control (― ● ―) cows. Only 
cows that were eventually fully vaccinated are included in this analysis.  
 
 
3.4.Statistical analysis 
  
3.4.1.Logistic regression and Cox regression analysis – risk 
factors for new IMI and cure of IMI. 
Risk of new IMI with Staph. aureus and CNS was analyzed by generalized 
linear regression analysis analyzing only new infections that occurred in 
cows calving after the 50/50 randomization had started. The final models 
are shown in Table 3.  
0
0,02
0,04
0,06
0,08
0,1
0,12
0,14
0,16
0,18
0,2
0 2 4 6 8 10
P
re
va
le
n
ce
 C
N
S 
IM
I
Month in Lactation
Control Vacc
71 
 
Table 3. Logistic regression of new Staph. aureus and CNS infections after the 
start of 50/50 randomization. Herd was used as a randome effect. 
   Staph. aureus  CNS 
Effect     Estimate(S.E.) 
Pr > 
|t| Estimate(S.E) 
Pr > 
|t| 
Intercept     -3.48(1.45) 0.02 -3.56(0.52) <.001 
Staph. aureus / 
CNS History     0.60(0.32) 0.06 -0.69(0.29) 0.02 
Month in lactation 1 -1.24(0.38) 0.00 -0.13(0.38) 0.73 
    2 -0.90(0.36) 0.01 0.91(0.33) 0.01 
    3 -0.68(0.35) 0.05 0.28(0.36) 0.44 
    4 -0.29(0.34) 0.40 0.16(0.39) 0.67 
    5 Baseline   Baseline   
    6 0.15(0.36) 0.68 0.48(0.37) 0.20 
    7 0.19(0.40) 0.64 -0.02(0.04) 0.96 
    8 0.32(0.35) 0.36 -0.23(0.39) 0.55 
Lactation   1 -1.62(0.27) <0.001 0.34(0.16) 0.04 
    2 -0.19(0.21) 0.35 0.03(0.17) 0.85 
    3 Baseline   Baseline   
Vaccination Vaccinated   0.14(0.20) 0.47 0.30(0.51) 0.45 
  Control   Baseline   Baseline   
Vaccination * 
Month in lactation 1 ns  -0.92(0.60) 0.13 
    2 ns  0.52(0.59) 0.38 
    3 ns  -1.01(0.58) 0.08 
    4 ns  -0.29(0.64) 0.65 
    5 ns  Baseline . 
    6 ns  -0.34(0.64) 0.60 
    7 ns  -0.32(0.76) 0.68 
    8 ns  -1.57(0.68) 0.02 
Herd B  -2.84(0.28) <.0001 -0.89(.14) <.0001 
 A  Baseline  Baseline  
 
For both Staph. aureus and CNS, new infections risk was not significantly 
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impacted by vaccination (P >0.05) when evaluated as a main effect. For 
Staph. aureus, new infections increased with increasing days in milk, with 
increasing parity and with having a history of a previous Staph. aureus 
infection. Regression of new CNS infections showed a significant 
interaction between month in lactation and vaccination where the risk of 
new infection was significantly lower (P <0.05) in two of the eight months 
in lactation. Risk of new CNS IMI showed no pattern across month in milk 
or parities, with only parity 1 showing a lower new infection risk. A history 
of a previous CNS IMI turned out to be protective for a next new CNS IMI. 
New infections are shown in Figure 6 for both Staph. aureus (6a) and CNS 
(6b).  
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Figure 6a. Incidence of new Staph. aureus IMI by months in lactation. Cows 
that eventually were fully vaccinated are included in this analysis. Per 
vaccination protocol, vaccinated cows have received two vaccinations in early 
lactation and receive the third and final dose at approximately 53 DIM.  
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Figure 6b: Incidence of new CNS IMI by months in lactation. Cows that 
eventually were fully vaccinated are included in this analysis. Per vaccination 
protocol, vaccinated cows have received two vaccinations in early lactation 
and receive the third and final dose at approximately 53 DIM. 
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Duration of infection was analyzed using Kaplan-Meier estimates of the 
survivor curve. The survivor curves are shown in Figure 7a for Staph. 
aureus and in Figure 7b for CNS.  
Figure 7a. Survivor curves estimated from the Cox regression for Staph. 
aureus infections. 
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Figure 7b. Survivor curves estimated from the Cox regression for CNS 
infections. 
 
 
Using Cox regression, the estimation of hazard of curing an IMI by 
vaccination group resulted in a significantly increased hazard of ending the 
presence of infection in vaccinated versus control animals (P <0.05). This 
was the case for both Staph. aureus and CNS, but CNS IMI had a higher 
rate of cure, resulting in a shorter duration of infection for CNS compared 
to Staph. aureus. There was also evidence for farm specific patterns, with 
higher risk of cure of Staph. aureus in farm B and higher risk of cure of CNS 
in farm A. 
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3.4.2. Modeling infections dynamics  
 
The monthly rate of new Staph. aureus infections was modeled in both 
herds using Poisson regression. First, it was evaluated whether there was 
evidence for contagious behavior of Staph. aureus by comparing a Poisson 
model with and without controlling for exposure to Staph. aureus (the offset 
term with and without I). The difference between the model with and without 
controlling for Staph. aureus exposure was highly significant (P < 0.001), 
indicating that there was a very clear contagious component to Staph. 
aureus infection in both herds.  
Modeling the impact of vaccination on the rate of new infections, correcting 
for the total exposure experience indicated that vaccination status was 
statistically significant in an interaction with parity group. Vaccination was 
associated with a lower transmission parameter for new infections in 
lactation 1, a non-significant but numerically lower transmission parameter 
in parity 2 and a significantly higher transmission parameter in lactations 3 
and higher (3+). In herd B, transmission of Staph. aureus was lower 
compared to herd A. These regression results are shown in Table 4.  
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Table 4. Regression results of Cox time to event analyses for both Staph. 
aureus and CNS. 
Parameter   
Estimat
e 
Standar
d Error 
Chi-
Square 
P-
value 
Hazar
d 
Ratio 
S.aureus:             
Vaccination
: Vaccinated 0.24 0.12 3.88 0.05 1.27 
  Control Baseline         
Herd B -0.61 0.12 26.74 
<.000
1 0.54 
  A Baseline         
              
CNS:             
Vaccination
: Vaccinated 0.37 0.08 20.99 
<.000
1 1.48 
  Control Baseline         
Herd B 0.25 0.08 9.13 <0.01 1.28 
  A Baseline         
 
Modeling the rate of cure of infection indicated that vaccination significantly 
increased the cure rate of Staph. aureus infections, this finding was 
consistent across lactation groups (P <0.0001), but different between the 
two herds. Herd B had a significantly better rate of cure compared to herd 
A (P <0.0001). These results are shown in Table 5. 
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Table 5. Modeling the rate of new Staph. aureus and CNS infections using a 
Poisson regression model. The unit of analyis in this model is a calendar 
month.  
  Staph. aureus 
 
CNS 
Effect  Category 
Estimate 
(S.E.) 
Pr > |t| 
 Estimate 
(S.E.) 
Pr > 
|t| 
Beta*, transmission 
parameter 
  
-1.22 
(0.10) 
<.0001 
 -
0.25(0.08) 
0.00 
Herd B 
-0.21 
(0.10) 
.03 
 -
0.46(0.07) 
<.0001 
  A Baseline     
Lactation group 1 
0.05 
(0.19) 
.80 
 -
0.24(0.08) 
0.00 
  2 
-0.18 
(0.14) 
.20 
 
0.11(0.09) 0.23 
  3+ Baseline     
Vaccine Vaccinated 
0.26 
(0.15) 
.08 
 -
0.22(0.07) 
0.00 
  Control Baseline     
Vaccine*lactation 
group 
Vaccinated * 
1 
-0.54 
(0.23) 
.02 
 
ns  
  
Vaccinated * 
2 
-0.43 
(0.20) 
.03 
 
ns  
  
Vaccinated * 
3+ 
Baseline  
 
ns  
Months since 50/50   
0.02 
(0.01) 
.01 
 
0.01(0.01) 0.25 
 
The monthly rate of new CNS IMI was also modeled using Poisson 
regression. The difference between the model with and without including 
exposure to CNS was highly significant, indicating that there was a very 
clear contagious component to CNS infection in both herds (P <0.00). 
There was a significantly lower transmission parameter in vaccinated cows 
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(P <0.00) in both herds. Comparing the two herds, farm B showed again a 
lower transmission compared to farm A (P <0.0001). These results are 
shown in Table 3. 
Modeling the rate of cure of CNS IMI indicated that vaccination significantly 
increased the cure rate of CNS infections (P <0.00), this finding was 
consistent across the two herds. Comparing the two herds, farm A had a 
significantly better cure and therefore a shorter duration compared to farm 
B. These results are shown in Table 4. 
Combining the transmission parameter and cure rate parameter into the 
overall basic reproduction ratio R0, resulted for Staph. aureus in an R0 
value of 0.89 (95% CI .44-1.57) for vaccinated animals and a value of 1.72 
(95% CI 1.06-3.17) for control cows. For CNS, the R0 value for vaccinated 
animals was 0.91 (95% CI 0.78 – 1.14) and for control cows this was 1.40 
(95% CI 1.16 – 1.70). 
 
3.5.Vaccine efficacy 
 
For the transmission parameters α and β, the vaccine efficacy is shown in 
the Table 6.  
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Table 6. Modeling the rate of new Staph. aureus and CNS infections using a 
Poisson regression model. The unit of analyis in this model is a calendar 
month. 
  Staph. aureus  
 
CNS 
Effect  Category 
Estimate 
(S.E.) 
Pr > |t| 
 Estimate 
(S.E.) 
Pr > |t| 
Beta*, transmission 
parameter 
  -1.22 (0.10) <.0001 
 
-0.25(0.08) 0.00 
Herd B -0.21 (0.10) .03  -0.46(0.07) <.0001 
  A Baseline     
Lactation group 1 0.05 (0.19) .80  -0.24(0.08) 0.00 
  2 -0.18 (0.14) .20  0.11(0.09) 0.23 
  3+ Baseline     
Vaccine Vaccinated 0.26 (0.15) .08  -0.22(0.07) 0.00 
  Control Baseline     
Vaccine*lactation 
group 
Vaccinated * 1 -0.54 (0.23) .02 
 
ns  
  Vaccinated * 2 -0.43 (0.20) .03  ns  
  Vaccinated * 3+ Baseline   ns  
Months since 50/50   0.02 (0.01) .01  0.01(0.01) 0.25 
 
The data indicated that vaccine efficacy for transmission is relatively low: 
in Staph. aureus it is either 25% in lactation 1 or non significant but positive 
(16%) and even negative (-30%) in lactations 2 and 3+ respectively. For 
CNS the transmission vaccine efficacy was 21%, and this was consistent 
across lactations. Vaccine efficacy for cure is moderate with a value of 41% 
for Staph. aureus and 16% for CNS. For Staph. aureus a significant 
difference in vaccine efficacy for cure was present between the two farms. 
Farm B showed a vaccine efficacy of cure of 52% and this was 30% for 
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farm A. When parameter estimates for transmission and cure were 
combined into a vaccine efficacy for the basic reproduction ratio, then an 
efficacy of 33% was present for reduction in basic reproduction ratio in CNS 
across herds and across lactations. For Staph. aureus vaccine efficacy was 
56% for lactation 1 animals, approximately 50% for lactation 2 animals and 
dropped further to 24% in lactation 3+ animals. When estimated across all 
animals in both herds, efficacy of vaccination with regard to the basic 
reproduction ratio for Staph. aureus was 45%. 
 
3.5.1. Clinical mastitis incidence 
 
Clinical mastitis incidence was modeled using Negative Binomial 
regression analysis. Both all clinical cases and bacteria-specific incidence 
of clinical cases were analyzed. The rates of mastitis for all cases and 
coliform cases are shown in Figure 8 and 9. In figure 10 and 11 the rate of 
Staph. aureus and CNS clinical mastitis are shown.  
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Figure 8. Clinical mastitis rate in vaccinated and control cows. All cases are 
shown. 
 
 
Figure 9. Clinical mastitis rate in vaccinated and control cows. Coliform cases 
are shown. 
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Figure 10. Clinical mastitis rate in vaccinated and control cows. Staph. aureus 
cases are shown. 
 
 
Figure 11. Clinical mastitis rate in vaccinated and control cows. CNS cases 
are shown. 
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For coliform clinical mastitis, Staph. aureus clinical mastitis and CNS 
clinical mastitis there were no significant difference between vaccinated 
cows and controls cows (P ≥ .05). In the regression model for all cases, 
vaccinated cows had significantly more mastitis compared to control cows. 
Their rate of mastitis was 1.35 times the rate in control cows, and this was 
statistically significant at P=.05.  
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4.DISCUSSION 
 
The key finding in this study was a first estimate of the efficacy of a 
Staphylococcal vaccine affecting the transmission of infection. The 
observed reduction in the basic reproduction ratio, R0, of approximately 
35% in CNS and 45% in Staph. aureus is encouraging but at the same time 
highlights that vaccination is only an additional tool in the control of 
staphylococcal infections on dairy farms. For both CNS and Staph. aureus 
vaccination resulted in moving the basic reproduction ratio from above to 
below the threshold of one. This basic reproduction ratio with a value below 
1 point towards a fade-out of infection in vaccinated groups. However, 
elimination of infection from a farm or a group of cows would only be 
possible when no new infection from sources other than shedding herd 
mates do occur. In reality, infections from other sources is quite likely 
(Barlow et al. 2013, Reksen et al. 2012). In addition, the variability in this 
estimate would allow individual farms to continue to have endemic 
staphylococcal IMI despite vaccination. Such variation in basic 
reproduction ratio of staphylococcal IMI has been observed before and 
were related to known infection risk factors (Lam et al. 1996, 1997, Reksen 
et al. 2012).  
For the analysis of the data, we focused our efficacy estimates on cows 
that received a full vaccination protocol. Despite the ambition to vaccinate 
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cows according to the label vaccination scheme, this was not always easy. 
Inaccurate estimation of duration of pregnancy, early loss of pregnancy, 
abortions and cows calving early were the most important reasons for 
incomplete vaccination. Given that incomplete vaccination due to the 
reasons described here is a reality in many herds, it is possible that our 
estimates of vaccine efficacy are overestimated compared to the truly 
observed vaccine efficacy under field conditions.  
The chosen study design with co-mingling of vaccinated and control cows 
allowed us the estimate vaccine efficacy within herd using a within herd 
randomization schedule. The difference between estimates of vaccine 
effects using simple regression analysis and a more elaborate 
mathematical modeling approach was large. Simple regression, resulting 
in estimate of direct vaccine efficacy showed no significant effects of 
vaccination on new infections. Simple regression analysis without 
controlling for exposure environment will provide an estimate of direct 
vaccine efficacy, whereas our modeling resulted in an unbiased estimated 
of overall population vaccine efficacy (Halloran et al. 1997). The estimate 
of direct vaccine efficacy in co-mingled populations is expected to be 
biased towards no effect (Halloran et al. 1998). Therefore, as expected, the 
estimates of vaccine efficacy were larger and likely unbiased when proper 
control for total exposure experience was included. Related to the 
significant overall population efficacy of vaccination was the finding that for 
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both Staph. aureus and CNS, the inclusion of total exposure experience in 
modelling of new infections was highly significant. The very same finding 
was reported before by Lam et al. (1996) and Barlow et al. (2013). 
Previous studies on staphylococcal vaccination in dairy cows as reviewed 
by Middleton et al. (2009) and Pereira et al. (2011) have shown relatively 
low vaccine efficacy or no vaccine efficacy at all. However, all the reviewed 
studies only reported direct vaccine efficacy and did not attempt to estimate 
overall population estimates. Since staphylococcal IMI are mostly 
subclinical and reducing infection transmission is the key outcome of 
interest, we would argue that carefully designed field studies with 
appropriate population dynamics based vaccine efficacy estimates are 
essential to allow unbiased efficacy estimates. The design and analyses 
used in the study that we report here may therefore be of interest for future 
studies on staphylococcal vaccine efficacy in dairy herds (Daum and 
Spellberg 2012). 
In the analysis of new infection risk with Staph. aureus, a significant 
interaction of month in lactation with vaccination group was observed, with 
an increased risk with increasing months in lactation. Similarly, risk of 
infection increased with lactation number. Vaccine effects were observed 
throughout all analyses that were performed. In the analyses that we 
performed we observed a significant decrease in prevalence of Staph. 
aureus in vaccinated cows compared to control cows, particularly later in 
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lactation (Figure 5a). Rate of new infection and prevalence of CNS tended 
to be lower in vaccinated cows compared to control cows (Figures 5b and 
6b). Duration of infection was significantly shorter in vaccinated cows 
compared to control cows in both Staph. aureus and CNS (Figure 7ab). 
The observed reduction in duration will benefit the affected cows but will 
also reduce the overall herd exposure experience of the other cows in the 
herd, resulting in an important contribution to indirect vaccine efficacy 
(Halloran et al. 1997, 1998). 
Modeling infection dynamics showed a significantly lower transmission 
parameter and rate of cure parameter for CNS across farms and groups of 
cows. For Staph. aureus a lower transmission parameter was present in 
first lactation animals and this impact of vaccination decreased with 
increasing lactation number. It has been shown before that IMI with Staph. 
aureus in older cows are less easily influenced by interventions (Barkema 
et al. 2006), most likely due to chronicity of the infection.  
Regarding clinical mastitis the bacteria-specific incidence were different in 
the two farms, infact in farm A Staph. aureus were the most bacterium 
diagnosed while in farm B were not the predominant. In both farms there 
were more clinical mastitis for vaccinated group but looking for Staph. 
aureus clinical mastitis and CNS clinical mastitis there were no significant 
difference between vaccinated cows and controls cows (P >0.05). 
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The farms showed a large difference in their ability to control infection 
during the study. For both farms, the prevalence of CNS remained more or 
less constant, but this was due to a slight increase in the control group and 
a decrease in prevalence in the vaccination group. Prevalence of Staph. 
aureus remained the same or slightly increased in farm A but dropped 
dramatically to a very low prevalence in farm B. Farm B was also actively 
culling Staph. aureus cows at a great rate compared to non Staph. aureus 
cows (P >0.05). The farm managers had no knowledge of the culture data 
during the trial, so the increase culling of Staph. aureus cows was based 
on the actual performance of the animals and not because of an increased 
culling policy for known Staph. aureus cows.  
The observed vaccine efficacy may vary depending on farm specific 
characteristics such as strain types (Smith et al. 1998, Barlow et al. 2013) 
and farm management practices (Lam et al. 1997) as we identified 
significant differences between farms. The known farm management 
practices associated with infection dynamics of Staph. aureus include 
treatment protocols, segregation and culling of known infected animals, 
milking procedures and milking equipment (Barkema et al. 2006). These 
differences in farm management practices will likely also be involved in 
determining the observed efficacy of staphylococcal vaccinations on dairy 
farms. On farms with good management practices, R0 for Staph. aureus 
would for example be reduced from 1.5 to .83, whereas on farm with poor 
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management vaccination would reduce R0 from 5 to 2.75. In the latter 
case, Staph. aureus would remain endemic despite vaccination, while in 
the first case Staph. aureus would eventually be eliminated due to 
vaccination. 
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5.CONCLUSIONS 
 
Vaccine efficacy was moderate in this field trial in two commercial dairy 
herds. Vaccination was able to reduce the basic reproduction ratio of CNS 
and Staph. aureus in both herds. The data indicated that vaccination will 
result in reduction of the basic reproduction ratio of Staph. aureus by 
approximately 45% and the basic reproduction ratio for CNS by 
approximately 35%. Particularly for Staph. aureus this efficacy was 
depending on the age group of the animals, where first lactation animals 
showed a significantly higher value compared to animals in third and higher 
lactation. The observed vaccine efficacy may vary depending on farm 
management practices as we identified significant differences between 
farms. Vaccination is a valuable tool in reducing incidence and prevalence 
of staphylococcal infection in herds. Vaccine utilization will need to be 
combined with excellent milking procedures, culling of known infected 
cattle and other management procedures to effectively reduce incidence 
and duration of infection. 
  
93 
 
6.REFERENCES 
1. Aarestrup, F. M., H. C. Wegener, T. Rosdahl, and N. E. Jensen. 1995. 
Staphylococcal and other bacterial species associated with 
intramammary infections in Danish dairy herds. Acta Vet. Scand. 
36:475–487. 
2. Aguilar, B., and M. Iturralde. 2001. Binding of a surface protein of 
Staphylococcus aureus to cultured ovine mammary gland epithelial 
cells. Veterinary Microbiology 82, 165–175. 
3. Almeida, R.A., W. Fang, and S.P. Oliver. 1999. Adherence and 
internalization of Streptococcus uberis to bovine mammary epithelial 
cells are mediated by host cell proteoglycans. FEMS Microbiology 
Letters 177, 313–317. 
4. Almeida, R.A., and S.P. Oliver. 2001. Interaction of coagulase-
negative Staphylococcus species with bovine mammary epithelial 
cells. Microbial Pathogenesis 31, 205–212. 
5. Amorena, B., R. Baselga, and B. Aguilar. 1990. Factors influencing 
the degree of in vitro bacterial adhesion to ovine mammary gland 
epithelial cells. Veterinary Microbiology 24, 43–53. 
6. Amorena, B. E. Gracia, M. Monzon, J. Leiva, C. Oteiza, J.L. Perez, 
J.L. Alabart, and J. Hernandez-Yago. 1999. Antibiotic susceptibility 
assay for Staphylococcus aureus in biofilms developed in vitro. 
Journal of Antimicrobial Chemotherapy 44, 43–55. 
94 
 
7. Andersen, S., I.R. Dohoo, R. Olde Riekerink, H. Stryhn, and Mastitis 
Research Workers' Conference. 2010. Diagnosing intramammary 
infections: evaluating expert opinions on the definition of 
intramammary infection using conjoint analysis. J. Dairy Sci. 
93:2966‐2975. 
8. Anderson, K. L., and R. L. Lyman. 2006. Long-term persistence of 
specific genetic types of mastitis-causing Staphylococcus aureus on 
three dairies. J. Dairy Sci. 89:4551–4556. 
9. Anguita-Alonso, P., A. Giacometti, O. Cirioni, R. Ghiselli, F. Orlando, 
V. Saba, G. Scalise, M. Sevo, M. Tuzova, R. Patel, and N. Balaban. 
2007. RNAIII-inhibiting-peptide-loaded polymethylmethacrylate 
prevents in vivo Staphylococcus aureus biofilm formation. 
Antimicrob. Agents Chemother. 51, 2594–2596. 
10. Artursson K., M. Nilsson-Öst, and K. Persson Waller. April 2010. An 
improved method to culture Staphylococcus aureus from bovine 
milk. Journal of Dairy Science, Volume 93, Issue 4. Pages 1534–
1538. http://dx.doi.org/10.3168/jds.2009-2544. 
11. Balaban, N., L.V. Collins, J.S. Cullor, E.B. Hume, E. Medina-Acosta, 
O. Vieira da Motta, R. O’Callaghan, P.V. Rossitto, M.E. Shirtliff, L.A. 
Serafim da Silveir, A. Tarkowski, and J.V. Torres. 2000. Prevention 
of diseases caused by Staphylococcus aureus using the peptide 
RIP. Peptides 21, 1301–1311. 
95 
 
12. Balaban, N., T. Goldkorn, Y. Gov, M. Hirshberg, N. Koyfman, H.R. 
Matthews, R.T. Nhan, B. Singh, and O. Uziel. 2001. Regulation of 
Staphylococcus aureus pathogenesis via target of RNAIII-activating 
Protein (TRAP). J. Biol. Chem. 276, 2658–2667. 
13. Balaban, N., A., Giacometti, O. Cirioni, Y. Gov, R. Ghiselli, F. 
Mocchegiani, C. Viticchi, M.S. Del Prete, V. Saba, G. Scalise, and 
G. Dell’Acqua. 2003. Use of the quorum-sensing inhibitor RNAIII-
inhibiting peptide to prevent biofilm formation in vivo by drug-
resistant Staphylococcus epidermidis. J. Infect. Dis. 187, 625–630. 
14. Balaban, N., Y. Gov, A. Giacometti, O. Cirioni, R. Ghiselli, F. 
Mocchegiani, F., Orlando, G. D’Amato, V. Saba, G. Scalise, S. 
Bernes, and A. Mor. 2004. A chimeric peptide composed of a 
dermaseptin derivative and an RNA III-inhibiting peptide prevents 
graft-associated infections by antibiotic-resistant staphylococci. 
Antimicrob. Agents Chemother. 48, 2544–2550. 
15. Balaban, N., P. Stoodley, C.A. Fux, S. Wilson, J.W. Costerton, and 
G. Dell’Acqua. 2005. Prevention of staphylococcal biofilm-
associated infections by the quorum sensing inhibitor RIP. Clin. 
Orthop. Relat. Res. 437, 48–54. 
16. Balaban, N., O. Cirioni, A. Giacometti, R. Ghiselli, J.B. Braunstein, 
C. Silvestri, F. Mocchegiani, V. Saba, and G. Scalise. 2007. 
Treatment of Staphylococcus aureus biofilm infection by the quorum-
96 
 
sensing inhibitor RIP. Antimicrob. Agents Chemother. 51, 2226–
2229. 
17. Bar, D., Y. T. Gröhn, R. N. González, J. A. Hertl, H. F. Schulte, G. 
Bennett, L. Tauer, and Y. H. Schukken. 2007. Effect of repeated 
episodes of generic clinical mastitis on milk yield in dairy cows. J. 
Dairy Sci. 90:4643–4653. 
18. Barkema, H. W., Y. H. Schukken, T. J. G. M. Lam, M. L. Beiboer, G. 
Benedictus, and A. Brand. 1998b. Management practices asso- 
ciated with low, medium, and high somatic cell counts in bulk milk. J. 
Dairy Sci. 81:1917–1927. 
19. Barkema, H.W., Y.H. Schukken, and R.N. Zadoks. Invited Review: 
The Role of Cow, Pathogen, and Treatment Regimen in the 
Therapeutic Success of Bovine Staphylococcus aureus Mastitis. 
June 2006. Journal of Dairy Science, Volume 89, Issue 6, Pages 
1877-1895. Http://dx.doi.org/10.3168/jds.S0022-0302(06)72256-1. 
20. Barkema, H. W., M. J. Green, A. J. Bradley, and R. N. Zadoks. 2009. 
The role of contagious disease in udder health. J. Dairy Sci. 
92:4717–4729. 
21. Barlow, J.W., R.N. Zadoks, and Y.H. Schukken. 2013. Effect of 
lactation therapy on Staphylococcus aureus transmission dynamics 
in two commercial dairy herds. BMC Vet. Res. 9:28-40.  
22. Barrio, B., F. Vangroenweghe, H. Dosogne, and C. Burvenich. 
97 
 
2000. Decreased neutrophil bactericidal activity during phagocytosis 
of a slime-producing Staphylococcus aureus strain. Veterinary 
Research 31, 603–609. 
23. Baselga, R., I. Albizu, M. De La Cruz, E. Del Cacho, M. Barberan, 
and B. Amorena. 1993. Phase variation of slime production in 
Staphylococcus aureus: implications in colonization and virulence. 
Infection and Immunity 61, 4857–4862. 
24. Bashandy, E. Y. and L. E. Heider. 1979. The effect of freezing of 
milk samples on the cultural results. Zentralbl. Veterinarmed. B 
26:1–6. 
25. Blowey, R. W. and P. W. Edmondson. 1995. Mastitis control in dairy 
herds. pp. 29. Ipswich, Farming Press. 
26. Borm, A. A., L. K. Fox, K. E. Leslie, J. S. Hogan, S. M. Andrew, S. 
P. Oliver, Y. H. Schukken, D. D. Hancock, C. T. Gaskins, W. E. 
Owens, and C. Norman. 2005. Transition intramammary antibi- otic 
therapy: Effects on udder health, milk production, and repro- ductive 
performance in dairy heifers. Page 364–369 in Proc. 4th Int. Dairy 
Fed. Mastitis Seminar, Maastricht, The Netherlands. Wageningen 
Acad. Publ., Wageningen, The Netherlands. 
27. Boss, R., J. Naskova, A. Steiner and H. and U. Graber. 2011. 
Mastitis diagnostics: Quantitative PCR for Staphylococcus aureus 
genotype B in bulk tank milk. J. Dairy Sci. 94:128–137. 
98 
 
28. Bradley A.J. September 2002. Bovine Mastitis: An Evolving 
Disease.. The Veterinary Journal, Volume 164, Issue 2, Pages 116–
128. http://dx.doi.org/10.1053/tvjl.2002.0724. 
29. Braem G., S. De Vliegher, B. Verbist, M. Heyndrickx, F. Leroy and 
L. De Vuyst. 2012. Culture-independent exploration of the teat apex 
microbiota of dairy cows reveals a wide bacterial species diversity. 
Vet Microbiol 157, 383-390. 
30. Braem, G., S. De Vliegher, B. Verbist, V. Piessens, E. Van Coillie, 
L. De Vuyst and F. Leroy. 2013. Unraveling the microbiota of teat 
apices of clinically healthy lactating dairy cows, with special 
emphasis on coagulase-negative staphylococci. J Dairy Sci 96, 
1499- 1510. 
31. Burvenich, C., A.J., Guidry and M.J., Paape. 1995. Natural defense 
mechanisms of the lactating and dry mammary gland. In: 
Proceedings of the Third IDF International Mastitis Seminar, vol. 1, 
Tel Aviv, Israel, pp. 3–13. 
32. Capurro, A., A. Aspán, H. E. Unnerstad, K. P. Waller, and K. 
Artursson. 2010. Identification of potential sources of 
Staphylococcus aureus in herds with mastitis problems. J. Dairy Sci. 
93:180–191. 
33. Cenci-Goga, B.T. M. Karama, P.V. Rossitto, R. A. Morgante, and 
J.S. Cullor. 2003. Enterotoxin production by Staphylococcus aureus 
99 
 
isolated from mastitic cows. J. Food Prot. 66, 1693–1696. 
34. Ceri, H., M.E. Olson, C. Stremick, R.R. Read, D. Morck, and A. 
Buret. 1999. The calgary biofilm device: new technology for rapid 
determination of antibiotic susceptibilities of bacterial biofilms. 
Journal of Clinical Microbiology 37, 1771–1776. 
35. Cirioni, O., A. Giacometti, R. Ghiselli, G. Dell’Acqua, Y. Gov, W. 
Kamysz, J. Lukasiak, F. Mocchegiani, F. Orlando, G. D’Amato, N. 
Balaban, V. Saba, and G. Scalise. 2003. Prophylactic efficacy of 
topical temporin A and RNAIII-inhibiting peptide in a subcutaneous 
rat Pouch model of graft infection attributable to staphylococci with 
intermediate resistance to glycopeptides. Circulation 108, 767–771. 
36. Cirioni, O., A. Giacometti, R. Ghiselli, G. Dell’Acqua, F. Orlando, F. 
Mocchegiani, C. Silvestri, A. Licci, V. Saba, G. Scalise, and N. 
Balaban. 2006. RNAIII-inhibiting peptide significantly reduces 
bacterial load and enhances the effect of antibiotics in the treatment 
of central venous catheter-associated Staphylococcus aureus 
infections. J. Infect. Dis. 193, 180–186. 
37. Cirioni, O., R. Ghiselli, D. Minardi, F. Orlando, F. Mocchegiani, C. 
Silvestri, G. Muzzonigro, V. Saba, G. Scalise, N. Balaban, and A. 
Giacometti. 2007. RNAIII-inhibiting peptide affects biofilm formation 
in a rat model of staphylococcal ureteral stent infection. Antimicrob. 
Agents Chemother. 51, 4518–4520. 
100 
 
38. Conley, J., M.E. Olson, L.S. Cook, H. Ceri, V. Phan, and H.D. 
Davies. 2003. Biofilm formation by group A streptococci: is there a 
relationship with treatment failure? Journal of Clinical Microbiology 
41, 4043–4048. 
39. Costerton, J.W., P.S. Stewart, E.P. Greenberg. 1999. Bacterial 
biofilms: a common cause of persistent infections. Science 284, 
1318–1322. 
40. Cucarella, C., M.A. Torma, C. Úbeda, M.P. Trotonda, M. Monzón, 
C. Peris, B. Amorena, I. Lasa, and J.R. Penadés. 2004. Role of 
biofilm-associated protein Bap in the pathogenesis of bovine 
Staphylococcus aureus. Infect. Immun. 72, 2177–2185. 
41. Daley, M. J., E. R. Oldham, T. J. Williams, and P. A. Coyle. 1991. 
Quantitative and qualitative properties of host polymorphonuclear 
cells during experimentally induced Staphylococcus aureus mastitis 
in cows. Am. J. Vet. Res. 52:474–479. 
42. Daum, R.S., and B. Spellberg. 2012. Progress toward a 
Staphylococcus aureus vaccine. Clin. Infect. Dis. 54:560‐567. 
43. Davidson, T. J., I. R. Dohoo, A. W. Donald, H. Hariharan, and K. 
Collins. 1992. A cohort study of coagulase negative staphylococcal 
mastitis in selected dairy herds in Prince Edward Island. Can. J. Vet. 
Res. 56:275–280. 
44. De Haas, Y., H.W. Barkema, and R.F. Veerkamp. 2002. The effect 
101 
 
of pathogen-specific clinical mastitis on the lactation curve for 
somatic cell count. Journal of Dairy Science 85, 1314–1323. 
45. Dell’Acqua, G., A. Giacometti, O. Cirioni, R. Ghiselli, V. Saba, G. 
Scalise, Y. Gov, and N. Balaban. 2004. Suppression of drug-
resistant Staphylococcal Infections by the quorum-sensing inhibitor 
RNAIII-inhibiting peptide. J. Infect. Dis. 190, 318–320. 
46. Deluyker, H. A., S. N. Van Oye, and J. F. Boucher. 2005. Factors 
affecting cure and somatic cell count after pirlimycin treatment of 
subclinical mastitis in lactating cows. J. Dairy Sci. 88:604–614. 
47. Devriese, L.A., V. Hajek, P. Oeding, S. Meyer, and K.H. Schleifer, 
1978. Staphylococcus hyicus (Sompolinsky 1953) comb. nov. and 
Staphylo- coccus hyicus subsp. chromogenes subsp. nov. Int. J. 
Syst. Bacteriol. 28, 482–490. 
48. Devriese, L.A., M. Vancanney, M. Baele, , M. Vaneechoutte, E. De 
Graef, C. Snauwaert, I. Cleenwerck, P. Dawyndt, J. Swings, A. 
Decostere, and F. Haesebrouck. 2005. Staphylococcus 
pseudointermedius sp. nov., a coagulase-positive species from 
animals. Int. J. Syst. Evol. Microbiol. 55, 1569–1573. 
49. Dingwell, R. T., K. E. Leslie, T. F. Duffield, Y. H. Schukken, L. 
DesCoteaux, G. P. Keefe, D. F. Kelton, K. D. Lissemore, W. Shew- 
felt, P. Dick, and R. Bagg. 2003. Efficacy of intramammary tilmicosin 
and risk factors for cure of Staphylococcus aureus infection in the 
102 
 
dry period. J. Dairy Sci. 86:159–168. 
50. Dinsmore, R. P., P. B. English, R. N. Gonzalez, and P. M. Sears. 
1992. Use of augmented cultural techniques in the diagnosis of the 
bacterial cause of clinical bovine mastitis. J. Dairy Sci. 75:2706– 
2712. 
51. Djabri, B., N. Bareille, F. Beaudeau, H. Seegers, and H. G. Allore. 
2002. Quarter milk somatic cell count in infected dairy cows: A meta-
analysis. Vet. Res. 33:335–357. 
52. Dohoo, I.R., J. Smith, S. Andersen, D.F. Kelton, S. Godden, and 
Mastitis Research Workers' Conference. 2011. Diagnosing 
intramammary infections: evaluation of definitions based on a single 
milk sample. J. Dairy Sci. 94:250‐261. 
53. Domenico, P., E. Gurzenda, A. Giacometti, O. Cirioni, R. Ghiselli, F. 
Orlando, M. Korem, V. Saba, G. Scalise, and N. Balaban. 2004. 
BisEDT and RIP act in synergy to prevent graft infections by resistant 
staphylococci. Peptides 25, 2047–2053. 
54. Donlan, R.M., and J.W. Costerton. 2002. Biofilms: survival 
mechanisms of clinically relevant microorganisms. Clinical 
Microbiology Reviews 15, 167–193. 
55. Dufour, S., J.-P. Roy and D. T. Scholl. Epidemiology of coagulase-
negative staphylococci intramammary infection in dairy cattle and 
the effect of bacteriological culture misclassification. 2012. J. Dairy 
103 
 
Sci. 95:3110–3124 http://dx.doi.org/10.3168/jds.2011-5164. 
56. Dunne Jr., W.M. 2002. Bacterial adhesion: seen any good biofilms 
lately? Clinical Microbiology Reviews 15, 155–166. 
57. Eberhart, R. J, L. J. Hutchinson, and S. B. Spencer. 1982. 
Relationships of bulk somatic cell counts to prevalence of 
intramammary infections and to indices of herd production. J. Food 
Prot. 45:1125–1128. 
58. Enright, M.C., N.P. Day, C.E. Davies, S.J. Peacock, and B.G. Spratt. 
2000. Multilocus sequence typing for characterization of methicillin-
resistant and methicillin-susceptible clones of Staphylococcus 
aureus. J. Clin. Microbiol. 38, 1008–1015. 
59. Evans, J. B., W. L. J. Bradford, and C. F. Niven. 1955. Comments 
concerning the taxonomy of the genera Micrococcus and 
Staphylococcus. Int. Bull. Bacteriol. Nomencl. Taxon. 5:61–66.  
60. Flügge, C. 1886. Die Mikroorganismen. F. C. W. Vogel. Leipzig, 
Germany. 
61. Fournier, C., P. Kuhnert, J. Frey, R. Miserez, M. Kirchhofer, T. 
Kaufmann, A. Steiner, and H. U. Graber. 2008. Bovine 
Staphylococcus aureus: Association of virulence genes, genotypes 
and clinical outcome. Res. Vet. Sci. 85:439–448. 
62. Fox, L.K., M. Gershman, D.D. Hancock, and C.T. Hutton. 1991. 
Fomites and reservoirs of Staphylococcus aureus intramammary 
104 
 
infections: the effect of milking time hygiene. Cornell Vet. 81, 183–
193. 
63. Fox, L.K. and J.M. Gay. 1993. Contagious mastitis in update on 
bovine mastitis. In: Anderson, K.L. (Ed.), Veterinary Clinics of North 
America: Food Animal Practice, vol. 9, no. 3. W.B. Saunders Co., 
Philadelphia, pp. 475–487. 
64. Fox, L.K., T.E. Besser, and S.M. Jackson, 1996. Evaluation of a 
coagulase-negative variant of Staphylococcus aureus as a cause of 
intramammary infections in a herd of dairy cattle. J. Am. Vet. Med. 
Assoc. 209, 1143–1146. 
65. Fox, L. K., R. N. Zadoks, and C. T. Gaskins. 2005. Biofilm 
production by Staphylococcus aureus associated with 
intramammary infection. Vet. Microbiol. 107:295–299. 
66. Giacometti, A., O. Cirioni, Y. Gov, R. Ghiselli, M.S. Del Prete, F. 
Mocchegiani, V. Saba, F. Orlando, G. Scalise, N. Balaban, and G. 
Dell’Acqua. 2003. RNA III inhibiting peptide inhibits in vivo biofilm 
formation by drug- resistant Staphylococcus aureus. Antimicrob. 
Agents Chemother. 47, 1979–1983. 
67. Giacometti, A., O. Cirioni, R. Ghiselli, G. Dell’Acqua, F. Orlando, G. 
D’Amato, F. Mocchegiani, C. Silvestri, M.S. Del Prete, M. Rocchi, N. 
Balaban, V. Saba, and G. Scalise. 2005. RNAIII-inhibiting peptide 
improves efficacy of clinically used antibiotics in a murine model of 
105 
 
staphylococcal sepsis. Peptides 26, 169–175. 
68. Gillespie, B. E., H. Moorehead, P. Lunn, H. H. Dowlen, D. L. 
Johnson, K. C. Lamar, M. J. Lewis, S. J. Ivey, J. W. Hallberg, S. T. 
Chester, and S. P. Oliver. 2002. Efficacy of extended pirlimycin 
hydrochloride therapy for treatment of environmental Streptococcus 
spp. and Staphylococcus aureus intramammary infections in 
lactating dairy cows. Vet. Ther. 3:373–380. 
69. Götz, F. 2002. Staphylococcus and biofilms. Mol. Microbiol. 43 (6), 
1367–1378. 
70. Graber, H. U., M. G. Casey, J. Naskova, A. Steiner, and W. 
Schaeren. 2007. Development of a highly sensitive and specific 
assay to detect Staphylococcus aureus in bovine mastitic milk. J. 
Dairy Sci. 90:4661–4669. 
71. Graber, H. U., J. Naskova, E. Studer, T. Kaufmann, M. Kirchhofer, 
M. Brechbühl, W. Schaeren, A. Steiner, and C. Fournier. 2009. 
Mastitis-related subtypes of bovine Staphylococcus aureus are 
characterized by different clinical properties. J. Dairy Sci. 92:1442–
1451. 
72. Gröhn, Y. T., D. J. Wilson, R. N. Gonzalez, J. A. Hertl, H. Schulte, 
G. Bennett, and Y. H. Schukken. 2004. Effect of pathogen- specific 
clinical mastitis on milk yield in dairy cows. J. Dairy Sci. 87:1619–
1628. 
106 
 
73. Gruet, P., P. Maincent, X. Berthelot, and V. Kaltsatos. 2001. Bovine 
mastitis and intramammary drug delivery: Review and perspec- 
tives. Adv. Drug Deliv. Rev. 50:245–259. 
74. Guidry, A., A. Fattom, A. Pattel, C. O’Brien, S. Shepherd, and J. 
Lohuis. 1998. Serotyping scheme for Staphylococcus aureus 
isolated from cows with mastitis. Am. J. Vet. Res. 59:1537–1539. 
75. Hagnestam, C., U. Emanuelson, and B. Berglund. 2007. Yield 
losses associated with clinical mastitis occurring in different weeks 
of lactation. J. Dairy Sci. 90:2260–2270. 
76. Hajek, V. 1976. Staphylococcus intermedius, a new species isolated 
from animals. Int. J. Syst. Bacteriol. 26, 401–408. 
77. Halasa, T., K. Huijps, O. Østerås, and H. Hogeveen. 2007. 
Economic effects of bovine mastitis and mastitis management: A 
review. Vet. Q. 29:18–31. 
78. Halloran, M.E., C.J. Struchiner, and I.M. Jr. Longini. 1997. Study 
designs for evaluating different efficacy and effectiveness aspects of 
vaccines. Am. J. Epidemiol. 146:789‐803. 
79. Halloran, M.E., R.M. Anderson, R.S. Azevedo‐Neto, W.J. Bellini, O. 
Branch, M.A. Burke, R. Compans, K. Day, L. Gooding, S. Gupta, J. 
Katz, O. Kew, H. Keyserling, R. Krause, A.A. E. Lal, Massad, A.R. 
McLean, P. Rosa, P. Rota, P. Wiener, S.G. Wynn, and D.M. 
Zanetta.1998. Population biology, evolution, and immunology of 
107 
 
vaccination and vaccination programs. Am. J. Med. Sci. 315:76‐86. 
80. Halloran, M.E., N.M. Ferguson, S. Eubank, I.M. Jr. Longini, D.A. 
Cummings, B. Lewis, S. Xu, C. Fraser, A. Vullikanti, T.C. Germann, 
D. Wagener, R. Beckman, K. Kadau, C. Barrett, C.A. Macken, D.S. 
Burke, and P. Cooley. 2008. Modeling targeted layered containment 
of an influenza pandemic in the United States. Proc. Natl. Acad. Sci. 
U.S.A.105(12):4639–44. 
81. Hamann, J., 2003. Definition of the physiological cell count 
threshold based on changes in milk composition. IDF Mastitis Newsl. 
25, 9–12. 
82. Harmon, R. J., and B. E. Langlois. 1989. Mastitis due to coagulase-
negative Staphylococcus species. Agri-Practice 10:29–32. Jarp, J. 
1991. Classification of coagulase-negative staphylococci isolated 
from bovine clinical and subclinical mastitis. Vet. Microbiol. 27:151–
158.  
83. Harmon, R. J. 1994. Physiology of mastitis and factors affecting 
somatic cell counts. J. Dairy Sci. 77:2103–2112. 
84. Haveri, M., S. Taponen, J. Vuopio-Varkila, S. Salmenlinna, and S. 
Pyörälä. 2005. Bacterial genotype affects the manifestation and 
persistence of bovine Staphylococcus aureus intramammary 
infection. J. Clin. Microbiol. 43:959–961. 
85. Haveri, M., A. Roslöf, L. Rantala, and S. Pyörälä. 2007. Virulence 
108 
 
genes of bovine Staphyloccus aureus from persistent and 
nonpersistent intramammary infections with different clinical 
characteristics. J. Appl. Micro- biol. 103, 993–1000. 
86. Hensen, S.M., M.J. Pavicic, J.A. Lohuis, J.A. De Hoog, and B. 
Poutrel. 2000a. Location of Staphylococcus aureus within the 
experimentally infected bovine udder and the expression of capsular 
polysaccharide type 5 in situ. Journal of Dairy Science 83, 1966–
1975. 
87. Hensen, S.M., M.J. Pavicic, J.A. Lohuis, and J.A. Poutrel. 2000b. 
Use of bovine primary mammary epithelial cells for the comparison 
of adherence and invasion ability of Staphylococcus aureus strains. 
Journal of Dairy Science 83, 418–429. 
88. Hertl, J. A., Y. T. Gröhn, J. D. G. Leach, D. Bar, G. J. Bennett, R. N. 
González, B. J. Rauch, F. L. Welcome, L. W. Tauer, and Y. H. 
Schukken. 2010. Effects of clinical mastitis caused by gram- positive 
and gram-negative bacteria and other organisms on the probability 
of conception in New York State Holstein dairy cows. J. Dairy Sci. 
93:1551–1560. 
89. Hertl, J. A., Y. H. Schukken, D. Bar, G. J. Bennett, R. N. González, 
B. J. Rauch, F. L. Welcome, L. W. Tauer, and Y. T. Gröhn. 2011. 
The effect of recurrent episodes of clinical mastitis caused by gram-
positive and gram-negative bacteria and other organisms on 
109 
 
mortality and culling in Holstein dairy cows. J. Dairy Sci. 94:4863–
4877. 
90. Hillerton, J. E., A. J. Bramley, R. T. Staker, and C. H. McKinnon. 
1995. Patterns of intramammary infection and clinical mastitis over a 
5 year period in a closely monitored herd applying mastitis control 
measures. J. Dairy Res. 62:39–50. 
91. Hillerton, J.E. and K.E. Kliem. 2002. Effective treatment of 
Streptococcus uberis clinical mastitis to minimize the use of 
antibiotics. Journal of Dairy Science 85, 1009–1014. 
92. Hogeveen, H., K. Huijps, and T. J. G. M. Lam. 2011. Economic 
aspects of mastitis: New developments. N. Z. Vet. J. 59:16–23. 
93. Houben, E.H., A.A. Dijkhuizen, J.A. Van Arendonk, and R.B. Huirne. 
1993. Short- and long-term production losses and repeatability of 
clinical mastitis in dairy cattle. Journal of Dairy Science 76, 2561– 
2578. 
94. Hwang, C. Y., S. I. Pak, and H. R. Han. 2000. Effects of autogenous 
toxoid-bacterin in lactating cows with Staphylococcus aureus 
subclinical mastitis. J. Vet. Med. Sci. 62:875–880. 
95. ISO (International Organization for Standardization). 2007. Milking 
machine installations—Mechanical tests. Method 6690-2007. ISO, 
Geneva, Switzerland. 
96. Janosi, S., A. Huszenicza, T. Horvath, F. Gemes, M. Kulcsar, and 
110 
 
G. Huszenicza. 2001. Bacteriological recovery after intramuscular or 
intracisternal spiramycin-based drying-off therapy. Acta Vet. Hung. 
49:155–162. 
97. Jefferson, K.K. 2004. What drives bacteria to produce biofilm? 
FEMS Microbiol. Lett. 236, 163–173. 
98. Jensen, M.A., J.A. Webster and N. Straus. 1993. Rapid 
identification of bacteria on the basis of polymerase chain reaction-
amplified ribosomal DNA spacer polymorphisms. Appl. Environ. 
Microbiol. 59, 945–952. 
99. Johnson, G.M., D.A., Lee, W.E., Regelmann, E.D., Gray, G., Peters, 
and P.G., Quie. 1986. Interference with granulocyte function by 
Staphylococcus epidermidis slime. Infection and Immunity 54, 13– 
20. 
100. Kiran, M.D., and N., Balaban, 2009. TRAP plays a role in stress 
response in Staphylococcus aureus. Int. J. Artif. Organs 32, 592–
599. 
101. Kumari, D.N., V. Keer, P.M. Hawkey, P. Parnell, N. Joseph, J.F. 
Richardson, and B. Cookson. 1997. Comparison and application of 
ribosome spacer DNA amplicon polymorphisms and pulsed-field gel 
electrophoresis for differentiation of methicillin-resistant 
Staphylococcus aureus strains. J. Clin. Microbiol. 35, 881–885. 
102. Lam, T.J., M.C. DeJong, Y.H. Schukken, and A. Brand. 1996. 
111 
 
Mathematical modeling to estimate efficacy of postmilking teat 
disinfection in split-udder trials of dairy cows. J. Dairy Sci. 79:62-70. 
103. Lam, T.J., J.H. van Vliet, Y.H. Schukken, F.J. Grommers, A. van 
Velden-Russcher, H.W. Barkema and A. Brand. 1997. The effect of 
discontinuation of postmilking teat disinfection in low somatic cell 
count herds. II. Dynamics of intramammary infections. Vet. Q. 
19(2):47-53. 
104. Leitner, G., E. Shoshani, O. Krifucks, M. Chaffer, and A. Saran. 
2000. Milk leukocyte population patterns in bovine udder infection of 
different etiology. J. Vet. Med. B 47, 581–589. 
105. Leitner, G., E., A. Lubashevsky, M. Glickman, A. Winkler, and Z. 
Saran Trainin. May 2003. Development of a Staphylococcus aureus 
vaccine against mastitis in dairy cows: I. Challenge trials. Veterinary 
Immunology and Immunopathology, Volume 93, Issues 1–2, 30, 
Pages 31–38.http://dx.doi.org/10.1016/S0165-2427(03)00051-5.  
106. Leitner G, O. Krifucks, M. Kiran, and N. Balaban. July 2011. 
Vaccine development for the prevention of staphylococcal mastitis in 
dairy cows Veterinary Immunology and Immunopathology, Volume 
142, Issues 1–2, 15, Pages 25–35. 
http://dx.doi.org/10.1016/j.vetimm.2011.03.023. 
107. Lopez-Leban, F., M.D. Kiran, R. Wolcott, and N. Balaban. 2010. 
Mechanisms of RIP, an effective inhibitor of chronic infections. Int. J. 
112 
 
Artif. Organs 33, 590–607. 
108. Lowy, F.D. 1998. Staphylococcus aureus infections. New Engl. J. 
Med. 339, 520–532. 
109. Luby, C. D., and J. R. Middleton. 2005. Efficacy of vaccination and 
antibiotic therapy against Staphylococcus aureus mastitis in dairy 
cattle. Vet. Rec. 157:89–90. 
110. Mack, D. 1999. Molecular mechanisms of Staphylococcus 
epidermidis biofilm formation. Journal of Hospital Infection 43 
(Suppl.), S113– 125. 
111. Mah, T.F., and G.A. O’Toole. 2001. Mechanisms of biofilm 
resistance to antimicrobial agents. Trends in Microbiology 9, 34–39. 
112. Mamo, W., M. Lindahl, and P. Jonsson. 1991. Enhanced virulence 
of Staphylococcus aureus from bovine mastitis induced by growth in 
milk whey. Vet. Microbiol. 27, 371–384. 
113. Matthews, K. R., R. J. Harmon, and B. E. Langlois. 1992. 
Prevalence of Staphylococcus species during the periparturient 
period in primiparous and multiparous cows. J. Dairy Sci. 75:1835–
1839.  
114. Matthews, K. R., S. J. Kumar, S. A. O’Conner, R. J. Harmon, J. W. 
Pankey, L. K. Fox, and S. P. Oliver. 1994. Genetic fingerprints of 
Staphylococcus aureus of bovine origin by polymerase chain-based 
DNA fingerprinting. Epidemiol. Infect. 112:177–186. 
113 
 
115. McDougall, S. 1998. Efficacy of two antibiotic treatments in curing 
clinical and subclinical mastitis in lactating dairy cows. N. Z. Vet. J. 
46:226–232. 
116. Melchior, M. B., J. Fink-Gremmels, and W. Gaastra. 2006a. 
Comparative assessment of the antimicrobial susceptibility of 
Staphylococcus aureus isolates from bovine mastitis in biofilm 
versus planktonic culture. J. Vet. Med. B Infect. Dis. Vet. Public 
Health 53:326–332. 
117. Melchior, M. B., H. Vaarkamp, and J. Fink-Gremmels. 2006b. 
Biofilms: A role in recurrent mastitis infections? Vet. J. 171:398–407. 
118. Melchior, M.B., H. Vaarkamp, and J. Fink-Gremmels. Biofilms: A 
role in recurrent mastitis infections? May 2006c. The Veterinary 
Journal, Volume 171, Issue 3, Pages 398–407. 
http://dx.doi.org/10.1016/j.tvjl.2005.01.006. 
119. Middleton, J. R., and L. K. Fox. 2001. Influence of Staphylococcus 
aureus strain on mammary quarter milk production. Pages 179– 180 
in Proc. 39th Annu. Mtg. Natl. Mastitis Counc., Atlanta, GA. Natl. 
Mastitis Counc., Madison, WI. 
120. Middleton, J.R., C.D. Luby, and D.S. Adams. 2009. Efficacy of 
vaccination against staphylococcal mastitis: a review and new data. 
Vet. Microbiol. 134:192-198. 
121. Monecke, S., and R. Ehricht, 2005. Rapid genotyping of methicillin-
114 
 
resistant Staphylococcus aureus (MRSA) isolates using miniaturised 
oligonucleotide arrays. Clin. Microbiol. Infect. 11, 825–833. 
122. Murdough, P. A., K. E. Deitz, and J. W. Pankey. 1996. Effects of 
freezing on the viability of nine pathogens from quarters with 
subclinical mastitis. J. Dairy Sci. 79:334–336. 
123. Neave, F. K., F. H. Dodd, R. G. Kingwill, and D. R. Westgarth. 
1969. Control of mastitis in the dairy herd by hygiene and 
management. J. Dairy Sci. 52:696–707. 
124. Novick, R.P., and E. Geisinger. 2008. Quorum sensing in 
staphylococci. Annu. Rev. Genet. 42, 541–564. 
125. Ogston, A. 1883. Micrococcus poisoning. J. Anat. Physiol. 
(London) 17:24–58. 
126. Oliver, S. P., and B. M. Jayarao. 1997. Coagulase-negative 
staphylococcal intramammary infections in cows and heifers during 
the nonlactating and periparturient periods. Zentralbl. Veterinarmed. 
B 44:355–363. 
127. Olson, M.E., H. Ceri, D.W. Morck, A.G. Buret, and R.R. Read. 
2002. Biofilm bacteria: formation and comparative susceptibility to 
antibiotics. Canadian Journal of Veterinary Research 66, 86– 92. 
128. Østerås, O., V. L. Edge, and S. W. Martin. 1999. Determinants of 
success or failure in the elimination of major mastitis pathogens in 
selective dry cow therapy. J. Dairy Sci. 82:1221–1231. 
115 
 
129. Østerås, O., L. Sølverød, and O. Reksen. 2006. Milk culture results 
in a large Norwegian survey—Effects of season, parity, days in milk, 
resistance, and clustering. J. Dairy Sci. 89:1010–1023. 
130. Owens, W.E., C.H. Ray, J.L. Watts, and R.J. Yancey. 1997. 
Comparison of success of antibiotic therapy during lactation and 
results of antimicrobial susceptibility tests for bovine mastitis. Journal 
of Dairy Science 80, 313–317. 
131. Park, J. Y., L. K. Fox, K. S. Seo, M. A. McGuire, Y. H. Park, F. R. 
Rurangirwa, W. M. Sischo, and G. A. Bohach. 2011. Detection of 
classical and newly described staphylococcal superantigen genes in 
coagulase-negative staphylococci isolated form bovine 
intramammary infections. Vet. Microbiol. 147:149–154. 
132. Pereira, U.P., D.G. Oliveira, L.R. Mesquita, G.M. Costa, and L.J. 
Pereira. 2011. Efficacy of Staphylococcus aureus vaccines for 
bovine mastitis: a systematic review. Vet. Microbiol. 148:117‐124. 
133. Persson, K., B. Amolina, and P. Jonsson. 1995. Inflammation in 
the bovine teat cistern induced by Staphylococcus aureus. Zentralbl. 
Vet. Med. B 42:435–442. 
134. Piessens, V., E. Van Coillie, B. Verbist, K. Supré, G. Braem, A. 
Van Nuffel, L. De Vuyst, M. Heyndrickx, and S. De Vliegher. 2011. 
Distribution of coagulase-negative Staphylococcus species from milk 
and environment of dairy cows differs between herds. J. Dairy Sci. 
116 
 
94:2933–2944. 
135. Piessens, V., S., De Vliegher, B., Verbist, G., Braem, A., Van 
Nuffel, L., De Vuyst, M. Heyndrickx, and E. Van Coillie. 2012. Intra-
species diversity and epidemiology varies among coagulase-
negative Staphylococcus species causing bovine intramammary 
infections. Vet Microbiol 155, 62-71. 
136. Pitkälä, A., M. Haveri, S. Pyörälä, V. Myllys, and T. Honkanen-
Buzalski. 2004. Bovine mastitis in Finland 2001—Prevalence, 
distribution of bacteria, and antimicrobial resistance. J. Dairy Sci. 
87:2433–2441. 
137. Poelarends, J. J., H. Hogeveen, O. C. Sampimon, and J. Sol. 2001. 
Monitoring subclinical mastitis in Dutch dairy herds. Pages 145– 149 
in Proc. 2nd Int. Symp. Mastitis and Milk Quality, Vancouver, BC, 
Canada. National Mastitis Counc., Madison, WI. 
138. Pyörälä, S.H., and E.O. Pyörälä, 1998. Efficacy of parenteral 
administration of three antimicrobial agents in treatment of clinical 
mastitis in lactating cows: 487 cases (1989–1995). Journal of 
American Veterinary Medical Association 212, 407–412. 
139. Pyörälä , S. 2005. Letter to the Editor: Concerning an article 
comparing the efficacy of local and systemic treatment of clinical 
mastitis. J. Dairy Sci. 88:1617. 
140. Pyörälä, S., and S. Taponen. 2009. Coagulase-negative 
117 
 
staphylococci— Emerging mastitis pathogens. Vet. Microbiol. 
134:3–8. 
141. Rachid, S., K. Ohlsen, W. Witte, J. Hacker, and W. Ziebuhr. 2000. 
Effect of subinhibitory antibiotic concentrations on polysaccharide 
intercellular adhesin expression in biofilm-forming Staphylococcus 
epidermidis. Antimicrobial Agents and Chemotherapy 44, 3357– 
3363. 
142. Radostits, O. M., K. E. Leslie and J. Fetrow. 1994. Herd Health: 
Food Animal Production Medicine. Philadelphia, PA., Saunders. p. 
233. 
143. Reksen, O., Y.T. Gröhn, J.W. Barlow, and Y.H. Schukken. 2012. 
Transmission dynamics of intramammary infections with coagulase-
negative staphylococci. J. Dairy Sci. 95(9):4899-4910. 
144. Roberson, J.R., L.K. Fox, D.D. Hancock, J.M. Gay, and T.E. 
Besser. 1996. Prevalence of coagulase-positive staphylococci, other 
than Staphylococcus aureus, in bovine mastitis. Am. J. Vet. Res. 57, 
54–58. 
145. Roberson, J. R. 2003. Establishing treatment protocols for clinical 
mastitis. Vet. Clin. North Am. Food Anim. Pract. 19:223–234. 
146. Rosenbach, F. J. 1884. Mikroorganismen bei den Wundinfections-
Krankheiten des Menschen. Wies-baden, Germany. 
147. Sampimon, O., H.W. Barkema, I. Berends, J. Sol, and T. Lam. 
118 
 
2009a. Prevalence of intramammary infection in Dutch dairy herds. 
J. Dairy Res. 76, 129–136. 
148. Sampimon, O.C., R.N. Zadoks, S. De Vliegher, K. Supre ́, F. 
Haesebrouck, H.W. Barkema, J. Sol, and T.J.G.M., Lam. 2009b. 
Performance of API Staph ID 32 and Staph-Zym for identification of 
coagulase-negative staphylococci isolated from bovine milk 
samples. Vet. Microbiol. 136, 300– 305. 
149. Sampimon, O., B. H. van den Borne, I. Santman-Berends, H. W. 
Barkema, and T. Lam. 2010. Effect of coagulase-negative 
staphylococci on somatic cell count in Dutch dairy herds. J. Dairy 
Res. 77:318-324. 
150. Santos, J. E. P., R. L. A. Cerri, M. A. Ballou, G. E. Higginbotham, 
and J. H. Kirk. 2004. Effect of timing of first clinical mastitis 
occurrence on lactational and reproductive performance of Holstein 
dairy cows. Anim. Reprod. Sci. 80:31–45. 
151. Schukken, Y. H., J. A. H. Smit, F. J. Grommers, D. Vandegeer, and 
A. Brand. 1989. Effect of freezing on bacteriologic culturing of 
mastitis milk samples. J. Dairy Sci. 72:1900–1906. 
152. Schukken, Y. H., R. N. Gonzalez, L. L. Tikofsky, H. F. Schulte, C. 
G. Santisteban, F. L. Welcome, G. J. Bennett, M. J. Zurakowski, and 
R. N. Zadoks. 2009a. CNS mastitis: Nothing to worry about? Vet. 
Microbiol. 134:9–14. 
119 
 
153. Schukken, Y. H., J. Hertl, D. Bar, G. J. Bennett, R. N. González, B. 
J. Rauch, C. Santisteban, H. F. Schulte, L. W. Tauer, F. L. Welcome, 
and Y. T. Gröhn. 2009b. Effects of repeated gram-positive and gram-
negative clinical mastitis episodes on milk yield loss in Holstein dairy 
cows. J. Dairy Sci. 92:3091–3105. 
154. Schukken, Y.H., V. Bronzo, C. Locatelli, C. Pollera, N. Rota, A. 
Casula, F. Testa, L. Scaccabarozzi, R. March, D. Zalduendo, R. Guix 
and P. Moroni. 2014. Efficacy of vaccination on Staphylococcus 
aureus and coagulase-negative staphylococci intramammary 
infection dynamics in 2 dairy herds. J. Dairy Sci. 97: 5250-5264. 
155. Sears, P. M., B. S. Smith, P. B. English, S. Herer, and R. N. 
Gonzalez. 1990. Shedding pattern of Staphylococcus aureus from 
bovine intramammary infections. J. Dairy Sci. 73:2785–2789. 
156. Sears, P. 2002. Staphylococcal vaccines: What are the new 
strategies? Pages 86–92 in Proc. 41st Ann. Mtg. Natl. Mastitis 
Counc., Orlando, Florida. Natl. Mastitis Counc. Inc., Madison, WI. 
157. Sears, P. M., and K. K. McCarthy. 2003. Management and 
treatment of staphylococcal mastitis. Vet. Clin. North Am. Food 
Anim. Pract. 19:171–185. 
158. Sérieys, F., Y. Raguet, L. Goby, H. Schmidt, and G. Friton. 2005. 
Comparative efficacy of local and systemic antibiotic treatment in 
lactating cows with clinical mastitis. J. Dairy Sci. 88:93–99. 
120 
 
159. Shephard, R. W., J. Malmo, and D. U. Pfeiffer. 2000. A clinical trial 
to evaluate the effectiveness of antibiotic treatment of lactating cows 
with high somatic cell counts in their milk. Aust. Vet. J. 78:763–768. 
160. Shoshani, E., G. Leitner, B. Hanochi, A. Saran, N.Y. Shpigel, and 
A. Berman. 2000. Mammary infection with Staphylococcus aureus in 
cows: progress from inoculation to chronic infection and its detection. 
Journal of Dairy Research 67, 155–169. 
161. Silvestri, L. G., and L. R. Hill. 1965. Agreement between 
deoxyroibonucleic acid base composition and taxonomic 
classification of Gram-positive cocci. J. Bacteriol. 90:136–140. 
162. Simojoki, H., P. Hyvönen, C. Plumed Ferrer, S. Taponen, and S. 
Pyörälä. 2012. Is the biofilm formation and slime producing ability of 
coagulase-negative staphylococci associated with the persistence 
and severity of intramammary infection? Vet. Microbiol. 158:344–
352. 
163. Simonetti, O., O. Cirioni, R. Ghiselli, G. Goteri, A. Scalise, F. 
Orlando, C. Silvestri, A. Riva, V. Saba, K.D. Madanahally, A. 
Offidani, N. Balaban, G. Scalise, and A. Giacometti. 2008. RNAIII-
inhibiting peptide enhances healing of wounds infected with 
methicillin resistant Staphylococcus aureus. Antimicrob. Agents 
Chemother. 52, 2205–2211. 
164. Smith, T.H., L.K. Fox, and J.R. Middleton. 1998. Outbreak of 
121 
 
mastitis caused by one strain of Staphylococcus aureus in a closed 
dairy herd. J. Am. Vet. Med. Assoc. 212:553-556. 
165. Smith, E. M., L. E. Green, G. F. Medley, H. E. Bird, L. K. Fox, Y. 
H. Schukken, J. V. Kruze, A. J. Bradley, R. N. Zadoks, and C. G. 
Dowson. 2005. Multilocus sequence typing of intercontinental bovine 
Staphylococcus aureus isolates. J. Clin. Microbiol. 43:4737–4743. 
166. Sol, J., O. C. Sampimon, J. J. Snoep, and Y. H. Schukken. 1994. 
Factors associated with bacteriological cure after dry cow treatment 
of subclinical Staphylococcus aureus mastitis with antibiotics. J. 
Dairy Sci. 77:75–79. 
167. Sol, J., O. C. Sampimon, J. J. Snoep, and Y. H. Schukken. 1997. 
Factors associated with bacteriological cure during lactation after 
therapy for subclinical mastitis caused by Staphylococcus aureus. J. 
Dairy Sci. 80:2803–2808. 
168. Sol, J., O.C., Sampimon, H.W., Barkema, and Y.H. Schukken, 
2000. Factors associated with cure after therapy of clinical mastitis 
caused by Staphylococcus aureus. Journal of Dairy Science 83, 
278– 284. 
169. Sol, J., O. C. Sampimon, E. Hartman, and H. W. Barkema. 2002. 
Effect of preculture freezing and incubation on bacteriological 
isolation from subclinical mastitis samples. Vet. Microbiol. 85:241–
249. 
122 
 
170. Sommerhäuser, J., B. Kloppert, W. Wolter, M. Zschöck, A. Sobiraj, 
and K. Failing. 2003. The epidemiology of Staphylococcus aureus 
infections from subclinical mastitis in dairy cows during a control 
programme. Vet. Microbiol. 96:91–102. 
171. Sordelli, D.O., F.R. Buzzola, M.I. Gomez, L. Steele-Moore, D. 
Berg, E. Gentilini, M. Catalano, A.J. Reitz, T. Tollersrud, G. 
Denamiel, P. Jeric, and J.C. Lee. 2000. Capsule expression by 
bovine isolates of Staphylococcus aureus from Argentina: genetic 
and epidemiologic analyses. J. Clin. Microbiol. 38, 846– 850. 
172. Stepan, J., R. Pantucek, and J. Doskar. 2004. Molecular 
diagnostics of clinically important Staphylococci. Folia Microbiol. 
(Praha) 49, 353– 386. 
173. Stewart, P.S. 1996. Theoretical aspects of antibiotic diffusion into 
microbial biofilms. Antimicrobial Agents Chemotherapy 40, 2517– 
2522. 
174. Stewart, P.S., and J.W. Costerton. 2001. Antibiotic resistance of 
bacteria in biofilms. Lancet 358, 135–138. 
175. Stoodley, P., K. Sauer, D.G. Davies, and J.W. Costerton. 2002. 
Biofilms as complex differentiated communities. Annual Review of 
Micro- biology 56, 187–209. 
176. Studer, E., W. Schaeren, J. Naskova, H. Pfaeffli, T. Kaufmann, M. 
Kirchhofer, and A. Steiner. 2008. A longitudinal field study to 
123 
 
evaluate the diagnostic properties of a quantitative real-time 
polymerase chain reaction-based assay to detect Staphylococcus 
aureus in milk. J. Dairy Sci. 91:1893–1902. 
177. Supré, K., F. Haesebrouck, R. N. Zadoks, M. Vaneechoutte, S. 
Piepers, and S. De Vliegher. 2011. Some coagulase-negative 
Staphylococcus species affect udder health more than others. J. 
Dairy Sci. 94:2329–2340. 
178. Swinkels, J. M., R. G. Rooijendijk, H. Hogeveen, and R. N. Zadoks. 
2005. Economic benefits of lactational treatment of subclinical 
Staphylococcus aureus mastitis. J. Dairy Sci. 88:4273–4287. 
179. Taponen, S., K. Dredge, B. Henriksson, A. M. Pyyhtia, L. Suojala, 
R. Junni, K. Heinonen, and S. Pyörälä. 2003a. Efficacy of 
intramammary treatment with procaine penicillin G vs. procaine 
penicillin G plus neomycin in bovine clinical mastitis caused by 
penicillin-susceptible, gram-positive bacteria—A double blind field 
study. J. Vet. Pharmacol. Ther. 26:193–198. 
180. Taponen, S., A. Jantunen, E. Pyörälä, and S. Pyörälä. 2003b. 
Efficacy of targeted 5-day combined parenteral and intramammary 
treatment of clinical mastitis caused by penicillin-susceptible or 
penicillin-resistant Staphylococcus aureus. Acta Vet. Scand. 44:53–
62. 
181. Taponen, S., H. Simojoki, M. Haveri, H. D. Larsen, and S. Pyörälä. 
124 
 
2006. Clinical characteristics and persistence of bovine mastitis 
caused by different species of coagulase-negative staphylococci 
identified with API or AFLP. Vet. Microbiol. 115:199–207. 
182. Taponen, S., J. Koort, J. Björkroth, H. Saloniemi, and S. Pyörälä. 
2007. Bovine intramammary infections caused by coagulase-
negative staphylococci may persist throughout lactation according to 
amplified fragment length polymorphism-based analysis. J. Dairy 
Sci. 90:3301–3307. 
183. Taponen, S. and S. Pyörälä. 2009. Coagulase-negative 
staphylococci as cause of bovine mastitis—Not so different from 
Staphylococcus aureus? Vet. Microbiol. 134:29–36. 
184. Thorberg, B.-M., I. Kühn, F. M. Aarestrup, B. Brändström, P. 
Jonsson, and M.-L. Danielsson-Tham. 2006. Pheno- and genotyping 
of Staphylococcus epidermidis isolated from bovine milk and human 
skin. Vet. Microbiol. 115:163–172. 
185. Thorberg, B.-M., M.-L. Danielsson-Tham, U. Emanuelson, and K. 
Persson Waller. October 2009. Bovine subclinical mastitis caused by 
different types of coagulase-negative staphylococci.Journal of Dairy 
Science, Volume 92, Issue 10, Pages 4962–4970 
http://dx.doi.org/10.3168/jds.2009-2184. 
186. Timms, L. L., and L. H. Schultz. 1987. Dynamics and significance 
of coagulase-negative staphylococcal intramammary infections. J. 
125 
 
Dairy Sci. 70:2648–2657. 
187. Vancraeynest, D., K. Hermans, and F. Haesenbrouck, 2004. 
Gentotypic and phenotypic screening of high and low virulence 
Staphylococcus aureus isolates from rabbits for biofilm formation 
and MSCRAMMs. Vet. Microbiol. 103, 241–247. 
188. Vasudevan, P., M.K. Nair, T. Annamalai, and K.S. 
Venkitanarayanan. 2003. Phenotypic and genotypic characterization 
of bovine mastitis isolates of Staphylococcus aureus for biofilm 
formation. Veterinary Microbiology 92, 179–185. 
189. Vieira-da-Motta, O., P.D. Ribeiro, W. Dias da Silva, and E. Medina-
Acosta. 2001. RNAIII inhibiting peptide (RIP) inhibits agr-regulated 
toxin production. Peptides 22, 1621–1627. 
190. Waage, S., H. R. Skei, J. Rise, T. Rogdo, S. Sviland, and S. A. 
Øde- gaard. 2000. Outcome of clinical mastitis in dairy heifers 
assessed by reexamination of cases one month after treatment. J. 
Dairy Sci. 83:70–76. 
191. Watson, D.L. 1982. Virulence of Staphylococcus aureus grown in 
vitro or in vivo. Res. Vet. Sci. 32, 311–315. 
192. Watts, J. L., J. W. Pankey, and S. C. Nickerson. 1984. Evaluation 
of the Staph-Ident and STAPHase systems for identification of 
staphylococci from bovine intramammary infections. J. Clin. 
Microbiol. 20:448–452. 
126 
 
193. Weller, T.M. 2000. Methicillin-resistant Staphylococcus aureus 
typing methods: which should be the international standard? J. 
Hosp. Infect. 44, 160–172. 
194. Wilson, D. J., R. N. Gonzalez, and P. M. Sears. 1995. Segregation 
or use of separate milking units for cows infected with 
Staphylococcus aureus: Effects on prevalence of infection and bulk 
tank somatic cell count. J. Dairy Sci. 78:2083–2085. 
195. Wilson, D. J., R. N. Gonzalez, and H. H. Das. 1997. Bovine mastitis 
pathogens in New York and Pennsylvania: Prevalence and effects 
on somatic cell count and milk production. J. Dairy Sci. 80:2592– 
2598. 
196. Yarwood, J.M., and P.M. Schlievert. 2003. Quorum sensing in 
Staphylococcus infections. Journal of Clinical Investigation 112, 
1620–1625. 
197. Yasuda, H., Y. Ajiki, J. Aoyama, and T. Yokota. 1994. Interaction 
between human polymorphonuclear leucocytes and bacteria 
released from in-vitro bacterial biofilm models. Journal of Medical 
Microbiology 41, 359–367. 
198. Zadoks, R. N., W. B. van Leeuwen, H. W. Barkema, O. C. 
Sampimon, H. Verbrugh, Y. H. Schukken, and A. van Belkum. 2000. 
Application of pulsed-field gel electrophoresis and binary typing as 
tools in veterinary clinical microbiology and molecular epidemiology 
127 
 
of bovine and human Staphylococcus aureus isolates. J. Clin. 
Microbiol. 38:1931–1939. 
199. Zadoks, R. N., H. G. Allore, H. W. Barkema, O. C. Sampimon, G. 
J. Wellenberg, Y. T. Gröhn, and Y. H. Schukken. 2001. Cow- and 
quarter-level risk factors for Streptococcus uberis and 
Staphylococcus aureus mastitis. J. Dairy Sci. 84:2649–2663. 
200. Zadoks, R. N., H. G. Allore, T. J. Hagenaars, H. W. Barkema, and 
Y. H. Schukken. 2002a. A mathematical model of Staphylococcus 
aureus control in dairy herds. Epidemiol. Infect. 129:397–416. 
201. Zadoks, R. N., W. B. Van Leeuwen, D. Kreft, L. K. Fox, H. W. 
Barkema, Y. H. Schukken, and A. van Belkum. 2002b. Comparison 
of Staphylococcus aureus isolates from bovine and human skin, 
milking equipment, and bovine milk by phage typing, pulsed-field gel 
electrophoresis, and binary typing. J. Clin. Microbiol. 40:3894– 3902. 
202. Zadoks, R.N., and J.L. Watts. 2009. Species identification of 
coagulase-negative staphylococci: genotyping is superior to 
phenotyping. Vet. Microbiol. 134, 20–28. 
203. Zecconi, A., R. Piccinini, A. Zepponi, and G. Ruffo. 1997. Recovery 
of Staphylococcus aureus from centrifuged quarter milk samples. J. 
Dairy Sci. 80:3058–3063. 
204. Ziv, G., and M. Storper. 1985. Intramuscular treatment of 
subclinical staphylococcal mastitis in lactating cows with penicillin G, 
128 
 
methicillin and their esters. J. Vet. Pharmacol. Ther. 8:276–283. 
205. Zopf, W. 1885. Die Spaltpilze. E. Trewendt. Breslau, Poland. 
 
 
 
 
 
  
129 
 
7.ACKNOWLEDGEMENTS 
 
I would like to express my special appreciation and thanks to my tutor 
Professor Paolo Moroni, you have been a big mentor for me. Your advice 
on both research as well as on my career have been priceless. Only you 
know how much is true what I just wrote. 
I would like to thank Professor Valerio Bronzo, my “Italian” boss. It is not 
so easy to find a boss like you, maybe due to your brilliant comments and 
suggestions. 
I would like to thank the persons who work at this trial, the persons who 
made it possible: Dr. Antonio Casula, Dr. Clara Locatelli, Dr. Claudia 
Pollera, Dr. Licia Scaccabarozzi and Dr. Francesco Testa. 
Thanks to everybody for these unforgettable years. 
I want also to thank Dr. Ynte Schukken. I want to thank not only for his help 
during the trial but also for the hospitality during my Ph.D. period at QMPS.  
I want to acknowledge the collaboration and support of the two farm owners 
and their staff in the execution of this trial. The research in this study was 
financially supported by Hipra, Spain. 
I also need to thank to Loredana, Matilde, Agnese and Sebastiano. They 
adopted me like an extra brothers in their family.  
130 
 
Thank to you, just arrived in my life. Your patience with me is incalculable.  
A special thanks to my family. Without you everything that I have done 
would have been impossible to do. I’m not speaking only about my Ph.D. 
period. Chapeau. 
 
 
